Skip to main content
PLOS Pathogens logoLink to PLOS Pathogens
. 2021 Jul 29;17(7):e1009797. doi: 10.1371/journal.ppat.1009797

A novel heteromeric pantothenate kinase complex in apicomplexan parasites

Erick T Tjhin 1,#, Vanessa M Howieson 1,#, Christina Spry 1, Giel G van Dooren 1, Kevin J Saliba 1,2,*
Editor: Sean T Prigge3
PMCID: PMC8366970  PMID: 34324601

Abstract

Coenzyme A is synthesised from pantothenate via five enzyme-mediated steps. The first step is catalysed by pantothenate kinase (PanK). All PanKs characterised to date form homodimers. Many organisms express multiple PanKs. In some cases, these PanKs are not functionally redundant, and some appear to be non-functional. Here, we investigate the PanKs in two pathogenic apicomplexan parasites, Plasmodium falciparum and Toxoplasma gondii. Each of these organisms express two PanK homologues (PanK1 and PanK2). We demonstrate that PfPanK1 and PfPanK2 associate, forming a single, functional PanK complex that includes the multi-functional protein, Pf14-3-3I. Similarly, we demonstrate that TgPanK1 and TgPanK2 form a single complex that possesses PanK activity. Both TgPanK1 and TgPanK2 are essential for T. gondii proliferation, specifically due to their PanK activity. Our study constitutes the first examples of heteromeric PanK complexes in nature and provides an explanation for the presence of multiple PanKs within certain organisms.

Author summary

Apicomplexans are a phylum of obligate intracellular parasites that cause diseases in humans and other animals, inflicting considerable burdens on human societies. During their intracellular stage, these parasites must scavenge vitamins from their host organisms in order to survive and proliferate. One such vitamin is pantothenate (vitamin B5), which parasites convert in a universal five-step pathway to the essential cofactor coenzyme A (CoA). The first reaction in the CoA biosynthesis pathway is catalysed by the enzyme pantothenate kinase (PanK). The genomes of humans and many other organisms, including apicomplexans, encode multiple PanK homologues, although in all studied examples, the functional PanK enzyme exists as a homodimer. In this study, we demonstrate that the two PanK homologues encoded in the genomes of the apicomplexans Plasmodium falciparum and Toxoplasma gondii, PanK1 and PanK2, exist as functional heteromeric complexes. We provide evidence that both PanK homologues contribute to the PanK activity in these parasites, and that both PanK1 and PanK2 are essential for the proliferation of T. gondii parasites specifically for their PanK activity. Our data describe the first known instances of heteromeric PanK complexes in nature and may explain why some organisms that express multiple PanKs harbour seemingly non-functional isoforms.

Introduction

Coenzyme A (CoA) is an essential enzyme cofactor in all living organisms [1]. CoA itself, and the CoA-derived phosphopantetheine prosthetic group required by various carrier proteins, function as acyl group carriers and activators in key cellular processes such as fatty acid biosynthesis, β-oxidation and the citric acid cycle. Pantothenate kinase (PanK) catalyses the first step in the conversion of pantothenate (vitamin B5) to CoA [2]. PanKs are categorised into three distinct types—type I, II and III—based on their primary sequences, structural fold, enzyme kinetics and inhibitor sensitivity. PanKs from all three types have been shown to exist as homodimers based on their solved protein structures [310]. All eukaryotic PanKs that have been characterised so far are type II PanKs. Interestingly, many eukaryotes (such as Arabidopsis thaliana [11,12], Mus musculus [1316] and Homo sapiens [1721]) express multiple PanKs and in some cases it is clear that these PanKs are not functionally redundant [15,22]. For example, mutations in only one of four type II PanKs in humans causes a neurodegenerative disorder known as PanK-associated neurodegeneration [17]. Some bacteria also express multiple PanKs. For example, some Mycobacterium [23], Streptomyces [7] and Bacillus [7,24,25] species have both type I and type III PanKs, while a select few bacilli (including the category A biodefense pathogen Bacillus anthracis) carry both a type II and type III PanK [7]. In some organisms harbouring multiple PanKs, it has not been possible to demonstrate functional activity for all enzymes. One of the four human type II PanKs was shown to be catalytically inactive [21,26], as is a type III PanK from Mycobacterium tuberculosis [23], and a type II PanK from B. anthracis [7]. The reason for the presence of multiple PanKs within certain cells, and the apparent inactivity of certain PanKs, is unclear.

Two putative genes coding for PanK enzymes have been identified in each of the genomes of the pathogenic apicomplexan parasites Plasmodium falciparum (PF3D7_1420600 (Pfpank1) and PF3D7_1437400 (Pfpank2)) and Toxoplasma gondii (TGME49_307770 (Tgpank1) and TGME49_235478 (Tgpank2)). We have recently shown that mutations in PfPanK1 alter PanK activity in P. falciparum, providing evidence that PfPanK1 is an active PanK, at least in the disease-causing stage of the parasite’s lifecycle [27]. The function of PfPanK2 and its contribution to PanK activity in P. falciparum is unknown. PfPanK2 contains a unique, large insert in a loop associated with the dimerisation of PanKs in their native conformation [8] and this may affect its ability to form a dimer, rendering it inactive [28]. No functional information is available on the putative T. gondii PanKs, but a genome-wide CRISPR-Cas9 screen of the T. gondii genome predicted that both PanK genes are important for parasite proliferation in vitro [29]. Similarly, a recent genome-wide insertional mutagenesis study of P. falciparum has predicted that mutations in either PfPanK1 or PfPanK2 result in significant fitness costs to the parasite [30]. These results suggest that the PanK2 proteins of these parasites play important role(s), although their exact function remains unclear.

In this study, we demonstrate that PanK1 and PanK2 from both P. falciparum and T. gondii are part of the same, multimeric protein complex in these parasites. This constitutes the first identification of heteromeric PanK complexes in nature. Furthermore, our data provide the first evidence that PanK2 contributes to, and is essential for, PanK function in apicomplexans.

Results

PfPanK1 and PfPanK2 are part of the same protein complex

The importance and role of PanK2 in apicomplexan parasites have not previously been established. To characterise the P. falciparum PanK2 homologue (PfPanK2), we first determined where in the parasite the protein localises. We episomally expressed PfPanK2-GFP in asexual blood stage P. falciparum parasites and found that PfPanK2-GFP is localised throughout the parasite cytosol and is not excluded from the nucleus (Fig 1A). This is a similar localisation to what we observed for PfPanK1-GFP previously [27]. Western blotting (S1 Fig, red arrow) of proteins separated by SDS-PAGE revealed that PfPanK2-GFP has a molecular mass consistent with the predicted mass of the fusion protein (~118 kDa; Fig 1B), which is slightly larger than the predicted mass of PfPanK1-GFP (~87 kDa; Fig 1B). As PanKs from other organisms exist as homodimers, we undertook blue native-PAGE to determine whether PfPanK1-GFP and PfPanK2-GFP exist in protein complexes. Interestingly, under native conditions, both PfPanK1-GFP and PfPanK2-GFP were found to be part of complexes that are ~240 kDa in mass (Fig 1B).

Fig 1. PfPanK1 and PfPanK2 are part of similar-sized protein complexes that possess PanK activity.

Fig 1

(A) Confocal micrographs showing the subcellular location of PfPanK2-GFP within trophozoite/schizont-stage P. falciparum-infected erythrocytes. The nuclei of the parasites are stained with DAPI. From left to right: Brightfield, GFP-fluorescence, DAPI-fluorescence, and merged images. Arrows indicate the plasma membranes of the erythrocyte (red) or the parasite (white). Scale bars represent 5 μm. (B) Denaturing and native western blot analyses of the GFP-tagged proteins in the PfPanK1-GFP and PfPanK2-GFP parasite lines. The expected sizes of the proteins are ~87 kDa for PfPanK1-GFP and ~118 kDa for PfPanK2-GFP. For reference, the molecular mass of the GFP tag is ~27 kDa. Western blots were performed with anti-GFP antibodies and each of the blots shown is representative of three independent experiments, each performed with a different batch of parasites. (C) The phosphorylation of [14C]pantothenate (initial concentration of 2 μM, ~10,000 counts per minute) over time by the immunopurified complex from lysates of parasites expressing PfPanK1-GFP (black circles), PfPanK2-GFP (white circles) and untagged GFP (grey circles). Data shown are representative of two independent experiments, each performed with a different batch of parasites and carried out in duplicate. Error bars represent range/2 and are not shown if smaller than the symbols.

To determine the activity and protein composition of these complexes, we set out to purify the PfPanK1-GFP and PfPanK2-GFP complexes by immunoprecipitation. As a control, we also purified untagged GFP. We verified that most of the GFP-tagged proteins were captured from the total lysates prepared from cell lines expressing the different proteins, with bands corresponding to PfPanK1-GFP, PfPanK2-GFP and the untagged GFP epitope tag detected in the bound fraction of the respective cell lines (S2 Fig). To determine whether the purified PfPanK1 and PfPanK2 complexes possess PanK activity, we performed a [14C]pantothenate phosphorylation assay (S1 Fig, orange arrow). We found that 50 − 60% of the [14C]pantothenate initially present in the reaction was phosphorylated within 90 min by the immunopurified complex from both the PfPanK1-GFP and PfPanK2-GFP lines (Fig 1C). Conversely, the immunopurified untagged GFP did not display PanK activity (Fig 1C). These experiments provide the first indication that PfPanK1 and PfPanK2 exist as part of an active PanK enzyme complex of similar mass in P. falciparum parasites. They also provide the first indication that PfPanK2 contributes to PanK activity in these parasites.

To elucidate the protein composition of the PfPanK1-GFP and PfPanK2-GFP complexes, the immunoprecipitated samples were subjected to mass spectrometry (MS)-based proteomic analysis (S1 Fig, green arrow; bound fractions of untagged GFP-expressing and 3D7 wild-type parasites were included as negative controls). Both PfPanK1 (36–50% coverage, S3 Fig) and PfPanK2 (29–49% coverage, S4 Fig) were unequivocally detected as the two most abundant proteins in the immunopurified complex from both the PfPanK1-GFP and PfPanK2-GFP lines (Fig 2A). Interestingly the next most abundant protein detected in both complexes was Pf14-3-3I (43–67% coverage, Figs 2A and S5). These results are consistent with PfPanK1, PfPanK2 and Pf14-3-3I being part of the same protein complex. Other proteins, such as M17 leucyl aminopeptidase (fourth most abundant), were also detected in the MS analysis, albeit with a comparatively fewer number of peptides (Fig 2A and S1 Table).

Fig 2. PfPanK1 and PfPanK2 are part of a single PanK complex that includes Pf14-3-3I.

Fig 2

(A) The four most abundant proteins identified in the MS analysis of proteins immunoprecipitated with GFP-Trap from the PfPanK1-GFP and PfPanK2-GFP lines. Data shown are representative of two independent analyses (1st and 2nd rep), each performed with a different batch of parasites. Proteins detected in the untagged GFP line or wild-type 3D7 parasite immunoprecipitations (negative controls) were removed. Only proteins with three or more peptides detected in both replicate co-immunoprecipitation experiments are shown. Proteins identified but which did not meet these criteria are shown in S1 Table. Proteins are listed in descending order according to the total number of peptides detected across all replicates (total peptides in all four columns). (B) The phosphorylation of [14C]pantothenate (initial concentration of 2 μM) over time by (i) lysates generated from Parent (white circles), PanOH-A (black triangles), PanOH-B (black squares) and CJ-A (black diamonds) parasite lines (reproduced from [27]) and (ii) proteins immunoprecipitated with GFP-Trap from Parent+PfPanK2-GFP (white circles), PanOH-A+PfPanK2-GFP (black triangles), PanOH-B+PfPanK2-GFP (black squares) and CJ-A+PfPanK2-GFP (black diamonds) parasite lysates. Values in (ii) are averaged from three independent experiments, each performed with a different batch of parasites and carried out in duplicate. Error bars represent SEM and are not shown if smaller than the symbols. (C) Native western blot analysis of the lysates and denaturing western blot analyses of the different GFP-Trap immunoprecipitation fractions generated from PfPanK1-GFP and PfPanK2-GFP parasite lines, with the untagged GFP line as a control. Protein samples used in the denaturing western blot were derived from the same immunoprecipitation depicted in S2 Fig. Western blots were performed with pan-specific anti-14-3-3 antibodies (previously shown to detect Plasmodium 14-3-3 [32]). Arrows indicate the position of 14-3-3-containing complexes of comparable masses in all three lines (solid arrow) and the complexes found only in the PfPanK1-GFP and PfPanK2-GFP lines (dashed arrow). The native blot shown is a representative of three independent experiments, while the denaturing blot is a representative of two independent experiments, each performed with a different batch of parasites.

Our group had previously generated three mutant strains, termed PanOH-A, PanOH-B and CJ-A, by drug-pressuring P. falciparum parasites with antiplasmodial pantothenate analogues [27]. These strains harbour mutations in PfPanK1 (D507N, ΔG95 and G95A, respectively) that affect PfPanK catalytic activity [27]. To test further whether PfPanK1 and PfPanK2 are part of the same protein complex, we introduced episomally-expressed PfPanK2-GFP into these parasite strains (the newly generated lines are designated with “+PfPanK2-GFP” superscript). We then immunopurified the PfPanK2-GFP complex from the PanOH-A+PfPanK2-GFP, PanOH-B+PfPanK2-GFP and CJ-A+PfPanK2-GFP lines, as well as from the wild type control (Parent+PfPanK2-GFP), and performed [14C]pantothenate phosphorylation assays with the complex derived from immunopurified PfPanK2-GFP (S1 Fig, orange arrow). As we reported previously, the PfPanK1 mutations alter the PfPanK activity of PanOH-A, PanOH-B and CJ-A parasites (using lysate, S1 Fig, blue arrow) such that the following rank order of enzyme activity relative to the Parent line is observed: PanOH-A > Parent > PanOH-B > CJ-A (Fig 2B(i), [27]). Notably, PanK activity of the complex immunopurified from the various PfPanK2-GFP-expressing mutant lines followed the same rank order: PanOH-A+PfPanK2-GFP > Parent+PfPanK2-GFP > PanOH-B+PfPanK2-GFP > CJ-A+PfPanK2-GFP (Fig 2B(ii)). This difference in pantothenate phosphorylation rates was not due to variations in the amount of PfPanK2-GFP protein in the immunopurified complexes used for the assays (S6 Fig). Further, the initial rate of pantothenate phosphorylation by the Parent lysate was 0.211 ± 0.026 (mean ± SEM) μmol/1012 cells/min (Fig 2B(i)) while that of the immunopurified complex from the Parent+PfPanK2-GFP line was 0.177 ± 0.016 (mean ± SEM) μmol/1012 cells/min (Fig 2B(ii)), demonstrating that the PanK activity in the immunopurified complexes is indistinguishable (95% CI = -0.119 to 0.051; include 0) from that observed in parasite lysates. Overall, the data shown in Fig 2B are consistent with PfPanK2-GFP associating with the mutant PfPanK1 from each cell line and indicate that both proteins are part of the same PanK complex in P. falciparum.

Our proteomic analysis identified Pf14-3-3I as being co-immunoprecipitated with both PfPanK1 and PfPanK2 (Fig 2A). To test whether Pf14-3-3I is a bona fide component of the PanK complex of P. falciparum, we performed western blotting with a pan-specific anti-14-3-3 antibody. Under native conditions (S1 Fig, red arrow), the 14-3-3 antibody detected a major protein band at <66 kDa (Fig 2C), which likely represents dimeric Pf14-3-3I of the parasite [31]. We also observed a protein complex of ~240 kDa in the PfPanK1-GFP, PfPanK2-GFP and untagged GFP lines (solid arrow, Fig 2C). In addition, a protein complex of slightly higher molecular mass, likely corresponding to the PanK complex that includes the GFP epitope tag, was also observed in the PfPanK1-GFP and PfPanK2-GFP lines but not the untagged GFP line (dashed arrow, Fig 2C). As a direct test for whether Pf14-3-3I exists in the same complex as PfPanK1 and PfPanK2, we performed western blotting on proteins immunopurified with anti-GFP antibodies from the PfPanK1-GFP, PfPanK2-GFP and untagged GFP parasite lines (S1 Fig, purple arrow). We found that Pf14-3-3I protein was detected in the immunopurified complex from both the PfPanK1-GFP and PfPanK2-GFP lines, but not in that purified from parasites expressing untagged GFP (Fig 2C). Together with the native western blot (Fig 1B) and proteomic (Fig 2A) analyses, these results are consistent with PfPanK1 and PfPanK2 being part of the same complex that also contains Pf14-3-3I, and that this complex is responsible for the PanK activity observed in the intraerythrocytic stage of P. falciparum.

TgPanK1 and TgPanK2 also constitute a single complex with PanK activity that is essential for parasite proliferation

Based on sequence similarity, TgPanK1 and TgPanK2 are homologous to their P. falciparum counterparts (S7 Fig). To begin characterising TgPanK1 and TgPanK2, we introduced the coding sequence for a mini-Auxin-Inducible Degron (mAID)-haemagglutinin (HA) tag into the 3’ region of the open reading frames of TgPanK1 or TgPanK2 in RH TATiΔKu80:TIR1 strain T. gondii parasites [33] also expressing a ‘tdTomato’ red fluorescent protein (RFP) (S8A Fig). Successful integration of the mAIDHA tag was verified by PCR (S8B Fig). Western blotting (S1 Fig, red arrow) revealed that the TgPanK1-mAIDHA and TgPanK2-mAIDHA proteins have molecular masses of ~160 and ~200 kDa, respectively (Fig 3A), corresponding to the predicted sizes of TgPanK1-mAIDHA (143 kDa) and TgPanK2-mAIDHA (189 kDa). When analysed under native conditions, TgPanK1-mAIDHA and TgPanK2-mAIDHA both exist in protein complexes of ~720 kDa in mass (Fig 3A).

Fig 3. TgPanK1 and TgPanK2 are part of a single protein complex with PanK activity.

Fig 3

(A) Denaturing and native western blot analyses of the HA-tagged proteins in TgPanK1-mAIDHA and TgPanK2-mAIDHA parasite lines. The expected sizes of TgPanK1-mAIDHA and TgPanK2-mAIDHA are ~143 kDa and ~189 kDa, respectively. Western blots were performed with an anti-HA antibody and each blot shown is a representative of three independent experiments, each performed with different batches of parasites. Denaturing western blots were also probed with anti-TgTOM40, which served as a loading control. (B) Western blot analysis of proteins from TgPanK1-GFP/TgPanK2-mAIDHA parasite lysates immunoprecipitated with GFP-Trap and anti-HA beads (TgPanK1-GFP is 160 kDa). Protein samples were collected before immunoprecipitation (Total), from the fraction not bound to the GFP-Trap/anti-HA beads (Unbound), and from the fraction bound to the GFP-Trap/anti-HA beads (Bound). Membranes were probed with anti-GFP and anti-HA antibodies, and the blot shown is representative of three independent experiments, each performed with different batches of parasites. TgTOM40 served as a control protein that is part of an unrelated protein complex. Bound fractions contain protein from 4 × as many cells as the total and unbound lanes. (C) The phosphorylation of [14C]pantothenate (initial concentration 2 μM) over time by protein samples immunoprecipitated with GFP-Trap from TgPanK1-GFP/TgPanK2-mAIDHA (black circles),TgPanK1-HA/TgPanK2-GFP (white circles) and untagged GFP (grey circles) lines. Data shown are representative of two independent experiments, each performed with a different batch of parasites and carried out in duplicate. Error bars represent the range/2 and are not shown if smaller than the symbols.

To investigate if TgPanK1 and TgPanK2 are part of the same ~720 kDa complex, we introduced a sequence encoding a GFP tag into the genomic locus of Tgpank1 in the TgPanK2-mAIDHA strain (S8A and S8C Fig). Co-immunoprecipitation experiments (S1 Fig, purple arrow) revealed that TgPanK1-GFP (160 kDa) co-purified with TgPanK2-mAIDHA (Fig 3B). Analogous experiments with a TgPanK1-HA/TgPanK2-GFP line, wherein we integrated a sequence encoding a GFP tag into the Tgpank2 locus and a sequence encoding a HA tag into the Tgpank1 locus (S8A and S8D Fig), yielded similar results (S9 Fig). We therefore conclude that, like PfPanK1 and PfPanK2 in P. falciparum (Figs 1 and 2), TgPanK1 and TgPanK2 are components of the same protein complex. We also tested whether the PanK complex in T. gondii contains an orthologue of 14-3-3I. Western blot analysis (S1 Fig, purple arrow) of the fractions from TgPanK1-GFP/TgPanK2-mAIDHA co-immunoprecipitation using a pan-14-3-3 antibody showed that Tg14-3-3 could be detected in T. gondii parasite lysates but not in the TgPanK complex (S10 Fig).

To determine whether the TgPanK1/TgPanK2 complex has pantothenate kinase activity, we immunopurified proteins from TgPanK1-GFP/TgPanK2-mAIDHA, TgPanK1-HA/TgPanK2-GFP and control (expressing untagged GFP) cell lines using GFP-Trap, and measured the ability of the purified proteins to phosphorylate pantothenate (S1 Fig, orange arrow). The samples purified from the TgPanK1-GFP/TgPanK2-mAIDHA and TgPanK1-HA/TgPanK2-GFP lines exhibited higher pantothenate phosphorylation activity than that from the control parasites expressing untagged GFP (Fig 3C). These findings indicate that, like the P. falciparum PanK complex (Figs 1 and 2), the TgPanK1/TgPanK2 complex possesses PanK activity.

Active PanK proteins from other organisms contain conserved nucleotide binding motifs [34,35]. As is the case for PfPanK2, the nucleotide-binding motifs of TgPanK2 deviate substantially from those of other eukaryotic PanKs (S7 Fig). It is therefore unclear whether pantothenate phosphorylation is catalysed solely by TgPanK1 or if TgPanK2 also contributes to PanK activity. To answer this, we first investigated whether TgPanK1 and TgPanK2 are important for parasite proliferation (S1 Fig, pink arrows). TgPanK1 and TgPanK2 were individually knocked down by exposing the mAID-regulated lines to 100 μM indole-3-acetic acid (IAA–a plant hormone of the auxin class), a concentration that we determined was not detrimental to wild-type parasite proliferation. TgPanK1-mAIDHA and TgPanK2-mAIDHA were degraded within an hour of exposing the parasites to IAA (Fig 4A). Both the TgPanK1-mAIDHA and TgPanK2-mAIDHA lines express RFP, which enabled us to monitor parasite proliferation using fluorescence growth assays, as described previously [36]. We measured proliferation of the TgPanK1-mAIDHA, TgPanK2-mAIDHA and parental lines cultured in the presence or absence of 100 μM IAA over seven days. In the absence of IAA, we observed a normal sigmoidal growth curve for all three lines (Fig 4B). By contrast, we observed a complete cessation of proliferation of the parasite lines expressing TgPanK1-mAIDHA and TgPanK2-mAIDHA, but not the parental strain, in the presence of 100 μM IAA (Fig 4B). These data indicate that both TgPanK1 and TgPanK2 are crucial for T. gondii proliferation and, notably, that neither can substitute for the other. To establish whether TgPanK1 and TgPanK2 are essential due to the PanK activity of the complex, we set out to complement the knocked down TgPanKs with a well-characterised PanK. The Staphylococcus aureus PanK (SaPanK) was selected for this purpose because (i) it is a type II PanK (like the TgPanKs), (ii) it has been shown to function as a homodimer (so only the one gene needs to be expressed) and (iii) it is refractory to negative feedback inhibition by CoA (allowing the enzyme to function even if the parasite maintains high levels of CoA). We therefore constitutively expressed Sapank fused with the coding sequence for a Ty1 epitope tag in both the TgPanK1-mAIDHA and TgPanK2-mAIDHA parasite lines, generating lines that we termed TgPanK1-mAIDHA+SaPanK-Ty1 and TgPanK2-mAIDHA+SaPanK-Ty1. The expression of the SaPanK protein in these strains was verified by immunofluorescence microscopy and western blot (S11 Fig). We measured the proliferation of the TgPanK1-mAIDHA+SaPanK-Ty1 and TgPanK2-mAIDHA+SaPanK-Ty1 lines in the presence and absence of 100 μM IAA, and compared this with the proliferation of the TgPanK1-mAIDHA, TgPanK2-mAIDHA and Parent lines. We obtained fluorescence measurements over a 7 day period and compared the proliferation of each strain when the Parent strain cultured in the absence of IAA reached mid-log phase. We found that both the TgPanK1-mAIDHA+SaPanK-Ty1 and TgPanK2-mAIDHA+SaPanK-Ty1 lines proliferated at a similar rate to the Parent control line when cultured in the presence of IAA, in contrast to the TgPanK1-mAIDHA and TgPanK2-mAIDHA lines, where minimal proliferation was observed (Fig 4C).

Fig 4. Expression of both TgPanK1 and TgPanK2 is necessary for PanK activity and for T. gondii tachyzoite proliferation.

Fig 4

(A) IAA-induced knockdown of TgPanK1-mAIDHA or TgPanK2-mAIDHA protein over time. Western blot analysis of TgPanK1-mAIDHA and TgPanK2-mAIDHA lines incubated with either 100 μM IAA (+IAA) for 1, 2 and 4 h or an ethanol vehicle control (0 h). Membranes were probed with anti-HA antibody to detect the TgPanK1-mAIDHA and TgPanK2-mAIDHA proteins, and with anti-TgTom40 as a loading control. Western blots shown are representative of three independent experiments, each performed with a different batch of parasites. (B) The effect of TgPanK1-mAIDHA or TgPanK2-mAIDHA knockdown on T. gondii tachyzoite proliferation. Parent, TgPanK1-mAIDHA and TgPanK2-mAIDHA lines (all expressing tdTomato RFP) were cultured over 7 days in the presence (red circles) or absence (black circles) of 100 μM IAA. Parasite proliferation was measured over time by assessing the RFP expression using a fluorescence reader. Graphs shown are representative of three independent experiments carried out in triplicate, each performed with a different batch of parasites. Error bars represent SD and are not shown if smaller than the symbols. (C) Complementation of TgPanK1 and TgPanK2 knockdown with SaPanK. SaPanK was constitutively expressed (+) in TgPanK1-mAIDHA+SaPanK-Ty1 (green bars) and TgPanK2-mAIDHA+SaPanK-Ty1 (blue bars) parasites. These lines were cultured alongside the non-complemented (-) TgPanK1-mAIDHA (green bars), TgPanK2-mAIDHA (blue bars) and parent lines (grey bars). All parasite lines were cultured either in the presence (+) or absence (-) of 100 μM IAA. Parasite proliferation was monitored 1–2 times daily for 7 days. Proliferation was compared when the Parent strain cultured in the absence of IAA was at the mid-log phase of parasite proliferation. Values are averaged from three independent experiments, each performed with a different batch of parasites and carried out in triplicate. Error bars represent SEM.

To test whether TgPanK2 is required for TgPanK1-dependent PanK activity in the parasites, we first investigated the stability of TgPanK1 when TgPanK2 was degraded by exposing the TgPanK1-GFP/TgPanK2-mAIDHA parasite line to 100 μM IAA over 6 hours. TgPanK1 abundance remained unchanged following TgPanK2 knockdown (Fig 5A), indicating that TgPanK1 stability or turnover is not dependent on TgPanK2. We next immunopurified TgPanK1-GFP from TgPanK1-GFP/TgPanK2-mAIDHA parasites that were incubated in the presence (+IAA) or absence (-IAA) of 100 μM IAA for 2–3 h, and tested the purified protein for PanK activity (S1 Fig, orange arrow). Although we observed similar abundance of purified TgPanK1-GFP between the +IAA and -IAA samples (Fig 5B), the samples immunoprecipitated from parasites exposed to IAA were devoid of PanK activity, whereas samples not exposed to IAA were able to phosphorylate pantothenate (Fig 5C). These data demonstrate that TgPanK1 is inactive in the absence of TgPanK2. Collectively, our studies on TgPanK1 and TgPanK2 reveal that (i) TgPanK1 and TgPanK2 are part of the same protein complex, (ii) expression of both proteins is required for PanK activity, and (iii) PanK activity of the complex is important for T. gondii proliferation during the disease-causing tachyzoite stage.

Fig 5. TgPanK2 is required for PanK activity in T. gondii parasites.

Fig 5

(A) Denaturing western blot analysis of the GFP- and HA-tagged proteins in the TgPanK1-GFP/TgPanK2-mAIDHA parasite line cultured in the absence or presence of IAA. TgPanK1-GFP/TgPanK2-mAIDHA parasites were incubated with either 100 μM IAA (+IAA) for 1, 2, 4 and 6 h, or an ethanol vehicle control (0 h). TgTOM40 served as a loading control. (B) Denaturing western blot analysis of the GFP- and HA-tagged proteins in the TgPanK1-GFP/TgPanK2-mAIDHA parasite line before and after immunopurification. TgPanK1-GFP/TgPanK2-mAIDHA parasites were incubated with either 100 μM IAA (+IAA), or an ethanol vehicle control (-IAA) for 2–3 h. The cells were lysed and a sample of total lysate (Total) was incubated with GFP-Trap. The GFP-Trap-immunoprecipitated protein (Bound) samples were then separated from the supernatant (Unbound) and all three fractions analysed by western blot. TgTOM40 served as a control protein that is not expected to be in the TgPanK complex. The western blot shown is a representative of three independent experiments, each performed with a different batch of parasites. (C) The phosphorylation of [14C]pantothenate (initial concentration of 2 μM) over time by GFP-Trap-immunoprecipitated protein samples from TgPanK1-GFP/TgPanK2-mAIDHA parasite lysates. The lysates were generated from parasites that were incubated in either the presence (+IAA) or absence (-IAA) of 100 μM IAA for 2–3 h. Data shown are averaged from three independent experiments, each performed with a different batch of parasites and carried out in duplicate. Error bars represent SEM and are not shown if smaller than the symbols.

Discussion

All PanKs characterised to date have been shown to exist as homodimers [310]. Here we present data consistent with PanK1 and PanK2 of the apicomplexan parasites P. falciparum and T. gondii forming a heteromeric complex (Figs 13), a hitherto undescribed phenomenon in nature.

There have been several attempts by us [unpublished] and others [3741] to express a functional PfPanK1. Whilst the protein has been successfully expressed in soluble form using various heterologous expression systems (Escherichia coli, insect cells, Saccharomyces cerevisiae), until recently [41], no study had reported PanK activity from the heterologously-expressed and purified protein. Nurkanto et al. [41] have recently reported the functional expression of PfPanK1 in E. coli. The expressed protein was initially insoluble but was solubilised using high concentrations of trehalose. The authors characterised the protein’s PanK activity (using an enzyme-coupled assay) and reported a pantothenate KM of 44.6 μM. This KM is more than two orders of magnitude higher than the KM that has been reported previously for PfPanK activity in parasite lysates [27,42,43]. The physiological significance of the PfPanK1 activity reported in the Nurkanto et al. study is therefore unclear. Our observations that the PanK activity of the immunoprecipitated PfPanK complex (Fig 2B(ii)), which includes the presence of PfPanK2 (as well as, potentially, additional proteins), is indistinguishable from the PanK activity of parasite lysates (Fig 2B(i)), is consistent with the PfPanK complex described here being responsible for the malaria parasite’s PanK activity.

A comparison of the amino acid sequences of P. falciparum and T. gondii PanKs with those of other type II PanKs, such as human PanK3 (HsPanK3), provides a possible explanation for why PanKs from these apicomplexan parasites exist in heteromeric complexes (S7 Fig). Each of the two identical active sites of the homodimeric HsPanK3 are formed by parts of both of its protomers. Certain residues form hydrogen bonds with pantothenate (Glu138, Ser195, Arg207 from one protomer and Val268’ and Ala269’ from the second protomer), while others interact to stabilise the active site (Asp137 with Tyr258’, and Glu138 with Tyr254’) [34,35] (S12 Fig). Notably, the hydrogen bond between Glu138 and Tyr254’ is important for the allosteric activation of the enzyme [35]. Critically, one of the important residues involved in active site stabilisation, Asp137, is only conserved in the PanK1 of P. falciparum and T. gondii but not their PanK2, while others, such as Tyr254’ and Tyr258’ are conserved in their PanK2 but not PanK1 (S7 and S12 Figs). This raises the possibility that PanK1 and PanK2 homodimers are not functional, and that only a heteromeric PanK1/PanK2 complex, with a single complete active site, can serve as a functional PanK enzyme in these apicomplexan parasites. This is consistent with the previous observation that two of the nucleotide-binding motifs of PfPanK2 deviate from those of other eukaryotic PanKs [28]. Whether the incomplete second active site plays an additional, as yet undetermined, role(s) remains to be seen. It should be noted that the PanKs of other apicomplexan parasites (including species from the genera Babesia, Cryptosporidium and Eimeria) exhibit a similar conservation of residues as that described above for P. falciparum and T. gondii (S13 Fig), raising the possibility that heteromeric PanK complexes are ubiquitous in Apicomplexa.

The apparent molecular weight of the PfPanK heterodimer complex (as determined from native western blotting) is consistent with that of a complex that includes PfPanK1, PfPanK2 and a Pf14-3-3I dimer (Fig 1B). However, due to various limitations of native gels [44], it is difficult to obtain an accurate estimate of the molecular weight of the complex. Although we cannot rule out the inclusion of other proteins in the PfPanK complex, such as M17 leucyl aminopeptidase (Fig 2A and S1 Table), we think that this is unlikely, since peptides from these proteins were detected at lower abundance than peptides from PfPanK1, PfPanK2 and Pf14-3-3I. The role of Pf14-3-3I in the heteromeric PfPanK complex (Fig 2A and 2C) is not clear. The 14-3-3 protein family comprises highly conserved proteins that occur in a wide array of eukaryotic organisms, including apicomplexans such as P. falciparum [32,4547]. Multiple isoforms of 14-3-3 are found to occur in every organism that expresses the protein [48]. 14-3-3 proteins bind to, and regulate, the function of proteins that are involved in a large range of cellular functions, including cell cycle regulation, signal transduction and apoptosis (reviewed in [49]). They typically bind to phosphorylated Ser/Thr residues on target proteins, and modify their target protein’s trafficking/targeting (reviewed in [50]), conformation, co-localisation, and/or activity (reviewed in [51]). The TgPanK heterodimer complex has a molecular weight that is much larger than the combined molecular weights of TgPanK1 and TgPanK2. Unfortunately, mass spectrometry analysis aimed at identifying the protein composition of the T. gondii PanK complex was unsuccessful, presumably because the native level of expression of the complex is too low. Nevertheless, we were unable to detect Tg14-3-3 in the TgPanK complex with a pan-specific 14-3-3 antibody even though we could detect it in T. gondii parasite lysates (S10 Fig). Whether this means that the presence of 14-3-3 in the P. falciparum PanK complex is not essential for enzyme activity, or if a different protein fulfils a similar role to 14-3-3 in the TgPanK complex, remains to be seen.

In this study, we have characterised, for the first time, PanK activity in T. gondii. The [14C]pantothenate phosphorylation data generated with the purified TgPanK complex (Fig 3C) provide the first biochemical evidence indicating that these putative PanKs are able to phosphorylate pantothenate. This finding, combined with the results of the knockdown and SaPanK complementation experiment in T. gondii (Fig 4B and 4C), as well as our demonstration that TgPanK1 alone is inactive (Fig 5), not only demonstrate the essentiality of TgPanK1 and TgPanK2 and their dependence on each other, but also show that the essentiality is due to their role in phosphorylating pantothenate.

T. gondii parasites inhabit metabolically active mammalian cells that contain their own CoA biosynthesis pathway. Our data indicate that T. gondii parasites are unable to scavenge sufficient downstream intermediates in the CoA biosynthesis pathway, including CoA, from their host cells, for their survival, and therefore must maintain their own active CoA biosynthesis pathway. The requirement for CoA biosynthesis in T. gondii, coupled with the intense investigation of this pathway as a drug target in P. falciparum [27,3941,5267], suggests that further characterisation of TgPanK, and the CoA biosynthesis pathway in T. gondii, could yield novel drug targets for chemotherapy.

It has been an open question as to why many organisms (eukaryotes [1121] and prokaryotes [7,2325]), including all apicomplexan parasites [68], express more than one PanK and why some PanKs appear to be non-functional [7,21,23] (either by analysis of their sequence or through failed attempts to demonstrate PanK activity experimentally). The data that we present here provides a possible answer to this question, at least in apicomplexan parasites.

Methods

Parasite and host cell culture

P. falciparum parasites were maintained in RPMI 1640 medium supplemented with 11 mM glucose (to a final concentration of 22 mM), 200 μM hypoxanthine, 24 μg/mL gentamicin and 6 g/L Albumax II as described previously [69]. T. gondii was cultured in human foreskin fibroblasts (HFF cells) as described previously [70]. T. gondii parasites were grown in flasks with a confluent HFF cell layer in either Dulbecco’s modified Eagle’s medium (DMEM) or complete RPMI 1640, with both media containing 2 g/L sodium bicarbonate and supplemented with 1% (v/v) fetal bovine serum (FBS), 50 units/mL penicillin, 50 μg/mL streptomycin, 10 μg/mL gentamicin, 0.2 mM L-glutamine, and 0.25 μg/mL amphotericin B.

Plasmid preparation and parasite transfection

The PfPanK1-GFP line was generated in a previous study [27], while the untagged GFP line was a generous gift from Professor Alex Maier (Research School of Biology, Australian National University, Canberra). A Pfpank2-pGlux-1 vector was generated for the overexpression of PfPanK2-GFP in 3D7 strain P. falciparum as detailed in S1 Text. The primers used are listed in S2 Table. The same construct was also transfected into each of the PfPanK1 mutants and their Parent line described previously by Tjhin et al. [27]. Transfections were performed with ring-stage parasites and transformants were subsequently selected and maintained using WR99210 (10 nM) as described previously [71].

Transgenic T. gondii parasite lines were generated using a CRISPR/Cas9 strategy as previously described in Shen et al. [72], which is detailed in the S1 Text. The guide RNAs, primers, and the sequences of gBlocks used are provided in S2 and S3 Tables.

The complementation lines TgPanK1-mAIDHA+SaPanK-Ty1 and TgPanK2-mAIDHA+SaPanK-Ty1 were created by expressing the S. aureus type II PanK gene (Sapank) in T. gondii under the regulation of the tubulin promoter (details in the S1 Text, S2 and S3 Tables).

Immunofluorescence assays and microscopy

Fixed PfPanK2-GFP-expressing 3D7 strain P. falciparum parasites within infected erythrocytes were observed and imaged with a Leica TCS-SP2-UV confocal microscope (Leica Microsystems) using a 63× water immersion lens as described in the S1 Text. To confirm the expression of SaPanK-Ty1 in the TgPanK1-mAIDHA+SaPanK-Ty1 line, immunofluorescence assays were performed based on the protocol described by van Dooren et al. [73]. T. gondii parasites were incubated with mouse anti-Ty1 antibodies (1:200 dilution). Secondary antibodies used were goat anti-mouse AlexaFluor 488 at a 1:250 dilution. The nucleus was stained with DAPI. Immunofluorescence images were acquired on a DeltaVision Elite system (GE Healthcare) using an inverted Olympus IX71 microscope with a 100× UPlanSApo oil immersion lens (Olympus) paired with a Photometrics CoolSNAP HQ2 camera. Images taken on the DeltaVision setup were deconvolved using SoftWoRx Suite 2.0 software. Images were adjusted linearly for contrast and brightness.

Polyacrylamide gel electrophoresis and western blotting

Parasite protein samples were analysed using either denaturing or blue native gels to determine the presence and abundance of a single protein or protein complex of interest, respectively. Briefly, mature trophozoite-stage P. falciparum parasites were isolated from infected erythrocytes by saponin lysis, as described previously [74]. Saponin-isolated parasites were then pelleted and lysed in the appropriate buffers (as detailed in the S1 Text). T. gondii protein samples were prepared as described previously, with samples for blue native-PAGE solubilised in Native PAGE sample buffer (ThermoFisher) containing 1% (v/v) Triton X-100 [73]. Protein samples generated from both P. falciparum and T. gondii parasites were separated by polyacrylamide gel electrophoresis (PAGE) in precast NuPAGE (4–12% or 12%) or NativePAGE (4–16%) gels (ThermoFisher) according to the manufacturer’s instructions with minor modifications (detailed in the S1 Text). The separated proteins were transferred to the appropriate membranes (nitrocellulose or polyvinylidene fluoride (PVDF)) and blocked (detailed in the S1 Text) before immunoblotting. Blocked membranes were exposed (45 min– 2 h) to specific primary and secondary antibodies to allow for the detection of the protein of interest. To visualise the protein band(s), membranes were incubated in Pierce enhanced chemiluminescence (ECL) Plus Substrate (ThermoFisher) according to the manufacturer’s instructions or home-made ECL substrate (0.04% w/v luminol, 0.007% w/v coumaric acid, 0.01% v/v H2O2, 100 mM Tris, pH 9.35). Protein bands were then either imaged onto X-ray films and scanned or visualised on a ChemiDoc MP Imaging System (Bio-Rad).

Flow cytometry

Saponin-isolated mature trophozoites from 3D7 wild-type, Parent+PfPanK2-GFP, PanOH-A+PfPanK2-GFP, PanOH-B+PfPanK2-GFP and CJ-A+PfPanK2-GFP cultures were subjected to flow cytometry analysis to determine the proportion of GFP-positive cells (S6 Fig). Aliquots of each isolated parasite suspension were diluted in a saline solution (125 mM NaCl, 5 mM KCl, 25 mM HEPES, 20 mM glucose and 1 mM MgCl2, pH 7.1) to a concentration of ~106–107 cells/mL in 1.2 mL Costar polypropylene cluster tubes (Corning) and sampled for flow cytometry analysis (in measurements of 100,000 cells, low sampling speed) with the following settings: forward scatter = 450 V (log scale), side scatter = 350 V (log scale) and AlexaFluor 488 = 600 V (log scale). The 3D7 wild-type cells were used to establish a gating strategy that defined a threshold below which parasites were deemed to be auto-fluorescent. This strategy was then applied in all analyses to determine the proportion of cells in each cell line that was GFP-positive (i.e. above the defined threshold).

Immunoprecipitations

In order to immunopurify GFP-tagged or HA-tagged proteins from parasite lysates, immunoprecipitation was performed using either GFP-Trap (high affinity anti-GFP alpaca nanobody bound to agarose beads; Chromotek) or anti-HA beads (Sigma-Aldrich), respectively. P. falciparum lysate was prepared from saponin-isolated trophozoites, and T. gondii lysate was prepared from tachyzoites, as described previously ([74] and [73], respectively). Immunoprecipitation was then performed (as detailed in the S1 Text). In P. falciparum experiments where the amount of immunoprecipitated proteins were to be standardised across cell lines and biological repeats, the number of GFP-positive cells to be used for lysate preparation was calculated by a combination of haemocytometer count and flow cytometry. All immunoprecipitated samples from Parent+PfPanK2-GFP, PanOH-A+PfPanK2-GFP, PanOH-B+PfPanK2-GFP and CJ-A+PfPanK2-GFP cell lines contained protein from 5 × 107 GFP-positive cells. Each of these samples was subsequently divided into two equal aliquots, one used in the [14C]pantothenate phosphorylation assay and the other for denaturing western blot.

When an aliquot of the immunoprecipitation sample (beads that have bound proteins from ~106–107 GFP-positive cells for P. falciparum and ~107–108 cells for T. gondii) was required for western blot, the bead suspension was centrifuged (2,500 × g, 2 min), the supernatant removed, and the beads resuspended in 50 μL sample buffer containing 2 × NuPAGE lithium dodecyl sulfate (LDS) sample buffer (ThermoFisher) and 2 × NuPAGE sample reducing agent (ThermoFisher). In some experiments, 10 μL aliquots of the total or unbound lysate fractions were each mixed with 10 μL of the same sample buffer. These samples were then boiled (95°C, 10 min) and 10 μL of each was then used in a denaturing western blot as described above.

[14C]Pantothenate phosphorylation assays

In order to determine the PanK activity of the protein(s) isolated in the GFP-Trap immunoprecipitation assays, the immunopurified complexes were used to perform a [14C]pantothenate phosphorylation time course. The bead suspensions containing the immunoprecipitated proteins from P. falciparum and T. gondii were centrifuged (2,500 × g, 2 min), the supernatant removed, and the beads resuspended in 250–300 μL (T. gondii) or 500 μL (for P. falciparum) buffer containing 100 mM Tris-HCl (pH 7.4), 10 mM ATP and 10 mM MgCl2 (i.e. all reagents were at twice the final concentration required for the phosphorylation reaction). Each time course was then initiated by the addition of 250–300 μL (for T. gondii) or 500 μL (for P. falciparum) 4 μM (0.2 μCi/mL) [14C]pantothenate in water (pre-warmed to 37°C), to the bead suspension. Aliquots of each reaction (50 μL in duplicate) were terminated at pre-determined time points by mixing with 50 μL 150 mM barium hydroxide preloaded within the wells of a 96-well, 0.2 μm hydrophilic PVDF membrane filter bottom plate (Corning). Phosphorylated compounds in each well were then precipitated by the addition of 50 μL 150 mM zinc sulfate to generate the Somogyi reagent [75], the wells processed, and the radioactivity in the plate determined as detailed previously [43]. Total radioactivity in each phosphorylation reaction was determined by mixing 50 μL aliquots of each reaction (in duplicate) thoroughly with 150 μL Microscint-40 (PerkinElmer) by pipetting the mixture at least 5 times, in the wells of an OptiPlate-96 microplate (PerkinElmer) [43].

Mass spectrometry of immunoprecipitated samples

The identities of the proteins co-immunoprecipitated from lysates of the wild-type 3D7, PfPanK1-GFP, PfPanK2-GFP and untagged GFP lines were determined by mass spectrometry. Aliquots of bead-bound co-immunoprecipitated samples were resuspended in 2 × NuPAGE LDS sample buffer and 2 × NuPAGE sample reducing agent and sent (at ambient temperature, travel time less than 24 h) to the Australian Proteomics Analysis Facility (Sydney) for processing and mass spectrometry analysis (as detailed in the S1 Text).

Fluorescent T. gondii proliferation assay

Fluorescent T. gondii proliferation assays were performed as previously described [36]. Briefly, 2000 parasites suspended in complete RPMI were added to the wells of optical bottom black 96 well plates (ThermoFisher) containing a confluent layer of HFF cells, either in the presence of 100 μM IAA dissolved in ethanol (final ethanol concentration of 0.1%, v/v) or with ethanol (0.1%, v/v) as a vehicle control, in triplicate. Fluorescent measurements (Excitation filter, 540 nm; Emission filter, 590 nm) using a FLUOstar OPTIMA Microplate Reader (BMG LABTECH) were taken over 7 days.

Knockdown of mAID protein

Flasks containing a confluent layer of HFF cells were seeded with TgPanK1-mAIDHA, TgPanK2-mAIDHA, TgPanK1-mAIDHA+SaPanK-Ty1 or TgPanK2-mAIDHA+SaPanK-Ty1 T. gondii parasites. While the parasites were still intracellular, 100 μM of IAA dissolved in ethanol (final ethanol concentration of 0.1%, v/v) was added to induce the knockdown of TgPanK1-mAIDHA or TgPanK2-mAIDHA, with ethanol (0.1%, v/v) added to another flask as a vehicle control. Flasks with IAA added were processed at 1, 2 and 4 h time points, and the control flask was processed at the 4-h time point. Parasite concentrations were determined using a haemocytometer and 1.5 × 107 parasites were resuspended in LDS sample buffer, and boiled at 95°C for 10 minutes. An aliquot from each sample was analysed by western blotting. The knockdown of TgPanK2-mAIDHA protein in the TgPanK1-GFP/TgPanK2-mAIDHA line was carried out using the same protocol, but with the addition of a 6 h time point.

Alignment of PanKs

PanK homologues from P. falciparum and T. gondii, and a selection of other type II PanKs from other eukaryotic organisms and S. aureus were aligned using PROMALS3D [76] (available at: http://prodata.swmed.edu/promals3d/promals3d.php). The default parameters were selected except for the ‘Identity threshold above which fast alignment is applied’ parameter, which was changed to “1” to allow for a more accurate alignment. The following PanK type II homologues were aligned (accession number included in brackets): Staphylococcus aureus (Q2FWC7); Saccharomyces cerevisiae (Q04430); Aspergillus nidulans (O93921); Homo sapiens PanK1 (Q8TE04), PanK2 (Q9BZ23), PanK3 (Q9H999) and PanK4 (Q9NVE7); Arabidopsis thaliana PanK1 (O80765) and PanK2 (Q8L5Y9); Plasmodium falciparum PanK1 (Q8ILP4) and PanK2 (Q8IL92) and Toxoplasma gondii PanK1 (A0A125YTW9) and PanK2 (V5B595).

Statistical analysis

Statistical analysis between the means of the pantothenate phosphorylation rate by the Parent lysate and that of the immunopurified complex from the Parent+PfPanK2-GFP line was carried out with unpaired, two-tailed, Student’s t test using GraphPad Prism 8 (GraphPad Software, Inc) from which the 95% confidence interval of the difference between the means (95% CI) was obtained. All regression analysis was done using SigmaPlot version 11.0 for Windows (Systat Software, Inc) or GraphPad Prism 8 (GraphPad Software, Inc).

Supporting information

S1 Table. List of proteins identified in the MS analysis of the GFP-Trap immunoprecipitated complexes from PfPanK1-GFP and PfPanK2-GFP lines.

Proteins detected in each immunoprecipitation experiment are listed in descending order according of the total number of peptides detected across the two replicates (total peptides in 1st and 2nd rep columns). Only proteins that are present in the immunoprecipitation fractions of both parasite lines and absent in the negative controls (bound fractions of untagged GFP and 3D7 parasite lysates) are shown. Proteins shown in Fig 2A are indicated in red.

(TIF)

S2 Table. List of oligonucleotides used in this study.

(TIF)

S3 Table. List of gBLOCK sequences used in this study.

(TIF)

S1 Fig. Overview of experimental workflow.

Flow chart highlighting the cell lines generated for the study and the main experimental steps that were performed. The coloured arrows represent final experimental results, and the associated figures within which the data are presented, are indicated under each experiment.

(TIF)

S2 Fig. GFP-Trap immunoprecipitation of proteins from PfPanK1-GFP, PfPanK2-GFP and untagged GFP lines.

Denaturing western blot analysis of the GFP-tagged proteins present in the total lysate, unbound and GFP-Trap-bound fractions of PfPanK1-GFP, PfPanK2-GFP and untagged GFP lines. Western blots were performed with anti-GFP antibody and the blot shown is representative of two independent experiments each performed with a different batch of parasites.

(TIF)

S3 Fig. MS coverage of PfPanK1.

PfPanK1 peptides detected in the two independent MS analyses of the GFP-Trap immunoprecipitation from the PfPanK1-GFP and PfPanK2-GFP lines. Residues in green were detected in either analysis with >95% confidence, while residues in orange were detected in either analysis with >90% (but <95%) confidence. Percentage coverage was calculated using only the residues labelled green.

(TIF)

S4 Fig. MS coverage of PfPanK2.

PfPanK2 peptides detected in the two independent MS analyses of the GFP-Trap immunoprecipitation from the PfPanK1-GFP and PfPanK2-GFP lines. Residues in green were detected in either analysis with >95% confidence, while residues in orange were detected in either analysis with >90% (but <95%) confidence. Percentage coverage was calculated using only the residues labelled green.

(TIF)

S5 Fig. MS coverage of Pf14-3-3I.

Pf14-3-3I peptides detected in the two independent MS analyses of the GFP-Trap immunoprecipitation from the PfPanK1-GFP and PfPanK2-GFP lines. Residues in green were detected in either analysis with >95% confidence, while residues in orange were detected in either analysis with >90% (but <95%) confidence. Percentage coverage was calculated using only the residues labelled green.

(TIF)

S6 Fig. Determining the amount of GFP-Trap bound PfPanK2-GFP for pantothenate phosphorylation assays.

(A) The proportion of GFP-positive saponin-isolated 3D7, Parent+PfPanK2-GFP, PanOH-A+PfPanK2-GFP, PanOH-B+PfPanK2-GFP and CJ-A+PfPanK2-GFP trophozoites was determined by FACS analysis. The forward scatter (FSC) intensity on each x-axis corresponds to cell size and the y-axis corresponds to the intensity of GFP fluorescence. The proportion of GFP-positive cells in each transgenic line (percentage value in each plot) was determined by using 3D7 trophozoites to set a gating threshold below which parasites were defined to be auto-fluorescent. Data shown are representative of three independent experiments, each performed prior to the [14C]pantothenate phosphorylation assays presented in Fig 2B(ii). The flow cytometry data were used to standardise the amount of PfPanK2-GFP immunoprecipitated from each cell line used in each [14C]pantothenate phosphorylation assay. (B) Denaturing western blot analysis of PfPanK2-GFP in the GFP-Trap immunoprecipitated complexes that were used in the [14C]pantothenate phosphorylation assays performed to generate the data in Fig 2B(ii). Western blots were performed with an anti-GFP antibody and each blot shows the relative amounts of PfPanK2-GFP immunopurified from the four different cell lines used in each of the three [14C]pantothenate phosphorylation experiment. The same volume of samples (10 μL per lane) was used for all three experiments.

(TIF)

S7 Fig. Multiple sequence alignment of representative Type II PanKs.

The conserved PHOSPHATE 1, PHOSPHATE 2, and ADENOSINE 1 motifs of the acetate and sugar kinases/Hsc70/actin (ASKHA) superfamily of kinases are labelled at the top of the alignment. The Glu (E) residue involved in catalysis and the Arg (R) residue involved in positioning the substrate, are shown on a black background. Residues that have been found to interact with pantothenate and acetyl-CoA in human PanK3 [34,35] are marked with a blue asterisk. Residues that were found to interact to stabilise the human PanK3 active site are marked with a red asterisk. The catalytic Glu (E) residue is marked with a red and blue asterisk as it is involved in both the interaction with pantothenate and the stabilisation of the active site through interaction with a Tyr (Y) residue of the opposite protomer. The numbers at the start and end of each sequence indicate the position of the first and last residue in the alignment, respectively. The lengths of insertions are specified within the square brackets and the total length of protein sequences are shown in round brackets. Residues within the ASKHA superfamily motifs and conserved residues are highlighted based on the consensus AA guide for the column as follows: identical = bold, hydrophobic (W,F,Y,M,L,I,V,A,C,T,H) = yellow, charged/polar/small (D,E,K,R,H/D,E,H,K,N,Q,R,S,T/A,G,C,S,V,N,D,T,P) = grey and Gly (G) = red. The two insertion regions (Ins 1 and Ins 2) common to eukaryotic type II PanKs, but absent in prokaryotic PanKs are indicated by the black horizontal bars, while the PfPank1/TgPanK1 and PfPanK2/TgPanK2 specific inserts are highlighted on a red and blue background, respectively. Conservation refers to the conservation index [77]. Values at and above the conservation index cut-off (5) are displayed above the amino acid. Consensus AA: refers to the consensus level alignment parameters for the consensus amino acid sequence. This is displayed if the weighted frequency of a certain class of residues in a position is above 0.8. Consensus symbols: conserved amino acids are in bold and uppercase letters; aliphatic (I, V, L): l; aromatic (Y, H, W, F): @; hydrophobic (W, F, Y, M, L, I, V, A, C, T, H): h; alcohol (S, T): o; polar residues (D, E, H, K, N, Q, R, S, T): p; tiny (A, G, C, S): t; small (A, G, C, S, V, N, D, T, P): s; bulky residues (E, F, I, K, L, M, Q, R, W, Y): b; positively charged (K, R, H): +; negatively charged (D, E): -; charged (D, E, K, R, H): c. Marked below the alignment, 85% consensus includes those residues that occur in either the superfamily motifs and/or conserved residues where the same residue occurs more than 85% (10 out of 13 sequences). Consensus secondary structure (ss) elements: h = alpha helix, e = beta strand. Species names are abbreviated as follows: Sa = Staphylococcus aureus, Sc = Saccharomyces cerevisiae, An = Aspergillus nidulans, Hs = Homo sapiens, At = Arabidopsis thaliana, Pf = Plasmodium falciparum and Tg = Toxoplasma gondii. The alignment was created using PROMALS3D [76].

(TIF)

S8 Fig. Schematic of the native and modified pank genomic loci in T. gondii and verification of the incorporation of the coding sequence for various epitope tags into the Tgpank1 and Tgpank2 loci.

(A) Schematic of theTgpank1 and Tgpank2 genomic loci, indicating the incorporation sites of the epitope tag coding sequence. The expected sizes of the PCR products when screened with each set of screening primers are shown above the corresponding epitope tag coding sequence. The screening primers are Tgpank1 screen fwd and rvs for Tgpank1 (referred to as Tgpank1 primers in panels B-D), and Tgpank2 screen fwd and rvs for Tgpank2 (referred to as Tgpank2 primers in panels B-D). Primers are detailed in S2 Table. (B) PCR analysis of the parental strain (TgParent), and singly-tagged TgPanK1-mAIDHA and TgPanK2-mAIDHA lines. Both TgPanK1-mAIDHA and TgPanK2-mAIDHA have successfully incorporated mAIDHA tags. (C) PCR analysis of the doubly-tagged TgPanK1-GFP/TgPanK2-mAIDHA line. CRISPR/Cas9 was utilised to incorporate a sequence encoding a TEV-GFP tag into the genomic locus of the Tgpank1 gene within the TgPanK2-mAIDHA line. (D) PCR analysis of the TgPanK1-HA/TgPanK2-GFP doubly-tagged line. CRISPR/Cas9 was utilised to incorporate a sequence encoding a TEV-HA tag into the genomic locus of the Tgpank1 gene and a sequence encoding a TEV-GFP tag into the genomic locus of the Tgpank2 gene.

(TIF)

S9 Fig. Anti-GFP and anti-HA immunoprecipitation of TgPanK1-HA/TgPanK2-GFP expressing parasites.

Anti-HA and anti-GFP denaturing western blot analysis of fractions from GFP-Trap and anti-HA immunoprecipitations performed using lysates prepared from the parasite lines expressing TgPanK1-HA/TgPanK2-GFP. The expected molecular masses of TgPanK1-HA and TgPanK2-GFP are 136 kDa and 206 kDa, respectively. The blot shown is representative of three independent experiments, each performed with a different batch of parasites. Denaturing western blots were also probed with anti-TgTOM40, which served as a control for a protein that is not part of the PanK complex.

(TIF)

S10 Fig. Absence of 14-3-3 from the TgPanK heteromeric complex.

Anti-HA, anti-GFP and anti-14-3-3 denaturing western blot analysis of fractions from GFP-Trap immunoprecipitation of lysates prepared from the parasite line expressing TgPanK1-GFP/TgPanK2-mAIDHA. The expected molecular masses of TgPanK1-GFP, TgPanK2-mAIDHA and 14-3-3 are approximately 160 kDa, 189 kDa and 37 kDa, respectively. The blots shown are representative of two independent experiments, each performed with a different batch of parasites.

(TIF)

S11 Fig. Expression of SaPanK-Ty1 in parasites expressing TgPanK1-mAIDHA and TgPanK2-mAIDHA.

(A) Anti-HA and anti-Ty1 denaturing western blot analysis of SaPanK-Ty1-complemented and non-complemented (i) TgPanK1-mAIDHA and (ii) TgPanK2-mAIDHA lines, in the absence or presence (for 1 h) of 100 μM IAA. The expected molecular masses of TgPanK1-mAIDHA, TgPanK2-mAIDHA and SaPanK-Ty1 are ~143 kDa, ~189 kDa and ~29 kDa, respectively. Denaturing western blots were also probed with anti-TgTOM40, which served as a loading control. Each blot shown is representative of three independent experiments, each performed with a different batch of parasites. (B) Fluorescence micrographs of a HFF cell infected with four tachyzoite-stage TgPanK1-mAIDHA+SaPanK-Ty1 parasites within a vacuole, indicating the presence of SaPanK-Ty1. From left to right: Differential interference contrast (DIC), tdTomato RFP (a marker of the nucleus and cytosol; red), anti SaPanK-Ty1 (green), and merged images. Scale bar represents 2 μm.

(TIF)

S12 Fig. Pantothenate binding site and interactions in H. sapiens PanK3.

(A) H. sapiens AMP-PNP-pantothenate-bound PanK3 crystal structure (PDB ID: 5KPR, Subramanian et al. [35]). The homodimeric protein is made up of two identical protomers (lilac and yellow) forming two identical active sites, each binding pantothenate (carbon atoms shown in green). The red square encompasses one of the active sites. (B) Magnification of the region outlined by the red square in (A). Residues from both protomers contribute to the stabilisation of the binding pocket (E138 forms a hydrogen bond with Y254’ and D137 with Y258’) and interact with pantothenate (E138, S195, R207, A269’ and V268’). Hydrogen bonds with and between the sidechains of these residues are shown in red. An apostrophe denotes residues from the lilac protomer. (C) List of residues annotated in the HsPanK3 model that participate in the stabilisation of the binding pocket (highlighted cyan), and a comparison to the equivalent residues in P. falciparum and T. gondii PanKs. The PanKs from P. falciparum and T. gondii do not individually contain the complete set of residues required for the stabilisation of the binding pocket, but the combination of residues (highlighted cyan) from PanK1 and PanK2 suggests that each PanK1/PanK2 heterodimer will have only one stabilised binding site.

(TIF)

S13 Fig. Multiple sequence alignment of active site stabilisation residues in apicomplexan PanKs.

The apicomplexan PanK residues corresponding to the HsPanK3 residues that are involved in the stabilisation of the binding pocket (D137, E138, Y254 and Y258) are highlighted in cyan if they are conserved and in grey if they are not conserved. The numbers before each alignment indicate the position of the first residue in the alignment. Each apicomplexan PanK is grouped into PanK1 or PanK2 based on their similarity to either PfPanK1/TgPanK1 or PfPanK2/TgPanK2, respectively. The alignment was created using PROMALS3D [76].

(TIF)

S1 Text. Supplementary Methods.

(DOCX)

Acknowledgments

Proteomics was undertaken at APAF, the infrastructure provided by the Australian Government through the National Collaborative Research Infrastructure Strategy (NCRIS). We are grateful to the Canberra Branch of the Australian Red Cross Lifeblood for the provision of red blood cells, and Professor Alex Maier (ANU) for the untagged GFP-expressing P. falciparum parasites and pGlux-1 plasmid.

Data Availability

All relevant data are within the manuscript and its Supporting Information files.

Funding Statement

ETT, VMH and CS were supported by Research Training Program scholarships from the Australian Government. CS was also funded by an NHMRC Overseas Biomedical Fellowship (1016357). This work was, in part, supported by a Project Grant (APP1129843) from the National Health and Medical Research Council to KJS and a Discovery Grant (DP150102883) from the Australian Research Council to GvD. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Leonardi R, Zhang Y-M, Rock CO, Jackowski S. Coenzyme A: back in action. Prog Lipid Res. 2005;44: 125–153. doi: 10.1016/j.plipres.2005.04.001 [DOI] [PubMed] [Google Scholar]
  • 2.Spry C, Kirk K, Saliba KJ. Coenzyme A biosynthesis: an antimicrobial drug target. FEMS Microbiol Rev. 2008;32: 56–106. doi: 10.1111/j.1574-6976.2007.00093.x [DOI] [PubMed] [Google Scholar]
  • 3.Yun M, Park CG, Kim JY, Rock CO, Jackowski S, Park H-W. Structural basis for the feedback regulation of Escherichia coli pantothenate kinase by coenzyme A. J Biol Chem. 2000;275: 28093–28099. doi: 10.1074/jbc.M003190200 [DOI] [PubMed] [Google Scholar]
  • 4.Das S, Kumar P, Bhor V, Surolia A, Vijayan M. Invariance and variability in bacterial PanK: a study based on the crystal structure of Mycobacterium tuberculosis PanK. Acta Crystallogr D Biol Crystallogr. 2006;62: 628–638. doi: 10.1107/S0907444906012728 [DOI] [PubMed] [Google Scholar]
  • 5.Yang K, Eyobo Y, Brand LA, Martynowski D, Tomchick D, Strauss E, et al. Crystal structure of a type III pantothenate kinase: insight into the mechanism of an essential coenzyme A biosynthetic enzyme universally distributed in bacteria. J Bacteriol. 2006;188: 5532–5540. doi: 10.1128/JB.00469-06 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Hong BS, Yun MK, Zhang Y-M, Chohnan S, Rock CO, White SW, et al. Prokaryotic type II and type III pantothenate kinases: The same monomer fold creates dimers with distinct catalytic properties. Structure. 2006;14: 1251–1261. doi: 10.1016/j.str.2006.06.008 [DOI] [PubMed] [Google Scholar]
  • 7.Nicely NI, Parsonage D, Paige C, Newton GL, Fahey RC, Leonardi R, et al. Structure of the type III pantothenate kinase from Bacillus anthracis at 2.0 Å resolution: implications for coenzyme A-dependent redox biology. Biochemistry. 2007;46: 3234–3245. doi: 10.1021/bi062299p [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Hong BS, Senisterra G, Rabeh WM, Vedadi M, Leonardi R, Zhang Y-M, et al. Crystal structures of human pantothenate kinases. Insights into allosteric regulation and mutations linked to a neurodegeneration disorder. J Biol Chem. 2007;282: 27984–27993. doi: 10.1074/jbc.M701915200 [DOI] [PubMed] [Google Scholar]
  • 9.Li B, Tempel W, Smil D, Bolshan Y, Schapira M, Park H-W. Crystal structures of Klebsiella pneumoniae pantothenate kinase in complex with N-substituted pantothenamides. Proteins. 2013;81: 1466–1472. doi: 10.1002/prot.24290 [DOI] [PubMed] [Google Scholar]
  • 10.Franklin MC, Cheung J, Rudolph MJ, Burshteyn F, Cassidy M, Gary E, et al. Structural genomics for drug design against the pathogen Coxiella burnetii. Proteins. 2015;83: 2124–2136. doi: 10.1002/prot.24841 [DOI] [PubMed] [Google Scholar]
  • 11.Kupke T, Hernández-Acosta P, Culiáñez-Macià FA. 4’-Phosphopantetheine and coenzyme A biosynthesis in plants. J Biol Chem. 2003;278: 38229–38237. doi: 10.1074/jbc.M306321200 [DOI] [PubMed] [Google Scholar]
  • 12.Tilton GB, Wedemeyer WJ, Browse J, Ohlrogge J. Plant coenzyme A biosynthesis: characterization of two pantothenate kinases from Arabidopsis. Plant Mol Biol. 2006;61: 629–642. doi: 10.1007/s11103-006-0037-4 [DOI] [PubMed] [Google Scholar]
  • 13.Rock CO, Calder RB, Karim MA, Jackowski S. Pantothenate kinase regulation of the intracellular concentration of coenzyme A. J Biol Chem. 2000;275: 1377–1383. doi: 10.1074/jbc.275.2.1377 [DOI] [PubMed] [Google Scholar]
  • 14.Rock CO, Karim MA, Zhang Y-M, Jackowski S. The murine pantothenate kinase (Pank1) gene encodes two differentially regulated pantothenate kinase isozymes. Gene. 2002;291: 35–43. doi: 10.1016/s0378-1119(02)00564-4 [DOI] [PubMed] [Google Scholar]
  • 15.Kuo YM, Duncan JL, Westaway SK, Yang H, Nune G, Xu EY, et al. Deficiency of pantothenate kinase 2 (Pank2) in mice leads to retinal degeneration and azoospermia. Hum Mol Genet. 2005;14: 49–57. doi: 10.1093/hmg/ddi005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Zhang Y-M, Rock CO, Jackowski S. Feedback regulation of murine pantothenate kinase 3 by coenzyme A and coenzyme A thioesters. J Biol Chem. 2005;280: 32594–32601. doi: 10.1074/jbc.M506275200 [DOI] [PubMed] [Google Scholar]
  • 17.Zhou B, Westaway SK, Levinson B, Johnson MA, Gitschier J, Hayflick SJ. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet. 2001;28: 345–349. doi: 10.1038/ng572 [DOI] [PubMed] [Google Scholar]
  • 18.Ni X, Ma Y, Cheng H, Jiang M, Ying K, Xie Y, et al. Cloning and characterization of a novel human pantothenate kinase gene. Int J Biochem Cell Biol. 2002;34: 109–115. doi: 10.1016/s1357-2725(01)00114-5 [DOI] [PubMed] [Google Scholar]
  • 19.Hörtnagel K, Prokisch H, Meitinger T. An isoform of hPANK2, deficient in pantothenate kinase-associated neurodegeneration, localizes to mitochondria. Hum Mol Genet. 2003;12: 321–327. doi: 10.1093/hmg/ddg026 [DOI] [PubMed] [Google Scholar]
  • 20.Ramaswamy G, Karim MA, Murti KG, Jackowski S. PPARα controls the intracellular coenzyme A concentration via regulation of PANK1α gene expression. J Lipid Res. 2004;45: 17–31. doi: 10.1194/jlr.M300279-JLR200 [DOI] [PubMed] [Google Scholar]
  • 21.Zhang Y-M, Chohnan S, Virga KG, Stevens RD, Ilkayeva OR, Wenner BR, et al. Chemical knockout of pantothenate kinase reveals the metabolic and genetic program responsible for hepatic coenzyme A homeostasis. Chem Biol. 2007;14: 291–302. doi: 10.1016/j.chembiol.2007.01.013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Leonardi R, Rehg JE, Rock CO, Jackowski S. Pantothenate kinase 1 is required to support the metabolic transition from the fed to the fasted state. PLoS One. 2010;5: e11107. doi: 10.1371/journal.pone.0011107 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Awasthy D, Ambady A, Bhat J, Sheikh G, Ravishankar S, Subbulakshmi V, et al. Essentiality and functional analysis of type I and type III pantothenate kinases of Mycobacterium tuberculosis. Microbiology. 2010;156: 2691–2701. doi: 10.1099/mic.0.040717-0 [DOI] [PubMed] [Google Scholar]
  • 24.Yocum RR, Patterson TA, Inc OB. Microorganisms and assays for the identification of antibiotics. U S Patent 6,830,898. 2004. [Google Scholar]
  • 25.Brand LA, Strauss E. Characterization of a new pantothenate kinase isoform from Helicobacter pylori. J Biol Chem. 2005;280: 20185–20188. doi: 10.1074/jbc.C500044200 [DOI] [PubMed] [Google Scholar]
  • 26.Yao J, Subramanian C, Rock CO, Jackowski S. Human pantothenate kinase 4 is a pseudo-pantothenate kinase. Protein Sci. 2019;28: 1031–1047. doi: 10.1002/pro.3611 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Tjhin ET, Spry C, Sewell AL, Hoegl A, Barnard L, Sexton AE, et al. Mutations in the pantothenate kinase of Plasmodium falciparum confer diverse sensitivity profiles to antiplasmodial pantothenate analogues. PLoS Pathog. 2018;14: e1006918. doi: 10.1371/journal.ppat.1006918 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Spry C, van Schalkwyk DA, Strauss E, Saliba KJ. Pantothenate utilization by Plasmodium as a target for antimalarial chemotherapy. Infect Disord Drug Targets. 2010;10: 200–216. doi: 10.2174/187152610791163390 [DOI] [PubMed] [Google Scholar]
  • 29.Sidik SM, Huet D, Ganesan SM, Huynh M-H, Wang T, Nasamu AS, et al. A genome-wide CRISPR screen in Toxoplasma identifies essential apicomplexan genes. Cell. 2016;166: 1423–1435.e12. doi: 10.1016/j.cell.2016.08.019 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Zhang M, Wang C, Otto TD, Oberstaller J, Liao X, Adapa SR, et al. Uncovering the essential genes of the human malaria parasite Plasmodium falciparum by saturation mutagenesis. Science. 2018;360. doi: 10.1126/science.aap7847 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Aitken A. 14-3-3 and its possible role in co-ordinating multiple signalling pathways. Trends Cell Biol. 1996;6: 341–347. doi: 10.1016/0962-8924(96)10029-5 [DOI] [PubMed] [Google Scholar]
  • 32.Lalle M, Currà C, Ciccarone F, Pace T, Cecchetti S, Fantozzi L, et al. Dematin, a component of the erythrocyte membrane skeleton, is internalized by the malaria parasite and associates with Plasmodium 14-3-3. J Biol Chem. 2011;286: 1227–1236. doi: 10.1074/jbc.M110.194613 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Brown KM, Long S, Sibley LD. Plasma membrane association by N-acylation governs PKG function in Toxoplasma gondii. MBio. 2017;8. doi: 10.1128/mBio.00375-17 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Leonardi R, Zhang Y-M, Yun MK, Zhou R, Zeng F-Y, Lin W, et al. Modulation of pantothenate kinase 3 activity by small molecules that interact with the substrate/allosteric regulatory domain. Chem Biol. 2010;17: 892–902. doi: 10.1016/j.chembiol.2010.06.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Subramanian C, Yun MK, Yao J, Sharma LK, Lee RE, White SW, et al. Allosteric regulation of mammalian pantothenate kinase. J Biol Chem. 2016;291: 22302–22314. doi: 10.1074/jbc.M116.748061 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Rajendran E, Hapuarachchi SV, Miller CM, Fairweather SJ, Cai Y, Smith NC, et al. Cationic amino acid transporters play key roles in the survival and transmission of apicomplexan parasites. Nat Commun. 2017;8: 14455. doi: 10.1038/ncomms14455 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Mehlin C, Boni E, Buckner FS, Engel L, Feist T, Gelb MH, et al. Heterologous expression of proteins from Plasmodium falciparum: results from 1000 genes. Mol Biochem Parasitol. 2006;148: 144–160. doi: 10.1016/j.molbiopara.2006.03.011 [DOI] [PubMed] [Google Scholar]
  • 38.Shen D, Huang Q, Sha Y, Zhou B. Cloning and confirmation of several potential pantothenate kinases and their interaction with pantothenate analogues. J Tsinghua Univ. 2008;48: 403–407. [Google Scholar]
  • 39.Chiu JE, Thekkiniath J, Choi J-Y, Perrin BA, Lawres L, Plummer M, et al. The antimalarial activity of the pantothenamide α-PanAm is via inhibition of pantothenate phosphorylation. Sci Rep. 2017;7: 14234. doi: 10.1038/s41598-017-14074-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Schalkwijk J, Allman EL, Jansen PAM, de Vries LE, Verhoef JMJ, Jackowski S, et al. Antimalarial pantothenamide metabolites target acetyl-coenzyme A biosynthesis in Plasmodium falciparum. Sci Transl Med. 2019;11: eaas9917. doi: 10.1126/scitranslmed.aas9917 [DOI] [PubMed] [Google Scholar]
  • 41.Nurkanto A, Jeelani G, Santos HJ, Rahmawati Y, Mori M, Nakamura Y, et al. Characterization of Plasmodium falciparum pantothenate kinase and identification of its inhibitors from natural products. Front Cell Infect Microbiol. 2021;11: 639065. doi: 10.3389/fcimb.2021.639065 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Saliba KJ, Kirk K. H+-coupled pantothenate transport in the intracellular malaria parasite. J Biol Chem. 2001;276: 18115–18121. doi: 10.1074/jbc.M010942200 [DOI] [PubMed] [Google Scholar]
  • 43.Spry C, Saliba KJ, Strauss E. A miniaturized assay for measuring small molecule phosphorylation in the presence of complex matrices. Anal Biochem. 2014;451: 76–78. doi: 10.1016/j.ab.2013.12.010 [DOI] [PubMed] [Google Scholar]
  • 44.Crichton PG, Harding M, Ruprecht JJ, Lee Y, Kunji ERS. Lipid, detergent, and Coomassie Blue G-250 affect the migration of small membrane proteins in blue native gels: mitochondrial carriers migrate as monomers not dimers. J Biol Chem. 2013;288: 22163–22173. doi: 10.1074/jbc.M113.484329 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Al-Khedery B, Barnwell JW, Galinski MR. Stage-specific expression of 14-3-3 in asexual blood-stage Plasmodium. Mol Biochem Parasitol. 1999;102: 117–130. doi: 10.1016/s0166-6851(99)00090-0 [DOI] [PubMed] [Google Scholar]
  • 46.Di Girolamo F, Raggi C, Birago C, Pizzi E, Lalle M, Picci L, et al. Plasmodium lipid rafts contain proteins implicated in vesicular trafficking and signalling as well as members of the PIR superfamily, potentially implicated in host immune system interactions. Proteomics. 2008;8: 2500–2513. doi: 10.1002/pmic.200700763 [DOI] [PubMed] [Google Scholar]
  • 47.Dastidar EG, Dzeyk K, Krijgsveld J, Malmquist NA, Doerig C, Scherf A, et al. Comprehensive histone phosphorylation analysis and identification of Pf14-3-3 protein as a histone H3 phosphorylation reader in malaria parasites. PLoS One. 2013;8: e53179. doi: 10.1371/journal.pone.0053179 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Rosenquist M, Sehnke P, Ferl RJ, Sommarin M, Larsson C. Evolution of the 14-3-3 protein family: does the large number of isoforms in multicellular organisms reflect functional specificity? J Mol Evol. 2000;51: 446–458. doi: 10.1007/s002390010107 [DOI] [PubMed] [Google Scholar]
  • 49.van Hemert MJ, Steensma HY, van Heusden GP. 14-3-3 proteins: key regulators of cell division, signalling and apoptosis. Bioessays. 2001;23: 936–946. doi: 10.1002/bies.1134 [DOI] [PubMed] [Google Scholar]
  • 50.Muslin AJ, Xing H. 14-3-3 proteins: regulation of subcellular localization by molecular interference. Cell Signal. 2000;12: 703–709. doi: 10.1016/s0898-6568(00)00131-5 [DOI] [PubMed] [Google Scholar]
  • 51.Bridges D, Moorhead GBG. 14-3-3 proteins: a number of functions for a numbered protein. Sci STKE. 2005;2005: re10. doi: 10.1126/stke.2962005re10 [DOI] [PubMed] [Google Scholar]
  • 52.Saliba KJ, Ferru I, Kirk K. Provitamin B5 (pantothenol) inhibits growth of the intraerythrocytic malaria parasite. Antimicrob Agents Chemother. 2005;49: 632–637. doi: 10.1128/AAC.49.2.632-637.2005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Saliba KJ, Kirk K. CJ-15,801, a fungal natural product, inhibits the intraerythrocytic stage of Plasmodium falciparum in vitro via an effect on pantothenic acid utilisation. Mol Biochem Parasitol. 2005;141: 129–131. doi: 10.1016/j.molbiopara.2005.02.003 [DOI] [PubMed] [Google Scholar]
  • 54.Spry C, Chai CLL, Kirk K, Saliba KJ. A class of pantothenic acid analogs inhibits Plasmodium falciparum pantothenate kinase and represses the proliferation of malaria parasites. Antimicrob Agents Chemother. 2005;49: 4649–4657. doi: 10.1128/AAC.49.11.4649-4657.2005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Spry C, Macuamule C, Lin Z, Virga KG, Lee RE, Strauss E, et al. Pantothenamides are potent, on-target inhibitors of Plasmodium falciparum growth when serum pantetheinase is inactivated. PLoS One. 2013;8: e54974. doi: 10.1371/journal.pone.0054974 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Fletcher S, Avery VM. A novel approach for the discovery of chemically diverse anti-malarial compounds targeting the Plasmodium falciparum Coenzyme A synthesis pathway. Malar J. 2014;13: 343. doi: 10.1186/1475-2875-13-343 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Saliba KJ, Spry C. Exploiting the coenzyme A biosynthesis pathway for the identification of new antimalarial agents: the case for pantothenamides. Biochem Soc Trans. 2014;42: 1087–1093. doi: 10.1042/BST20140158 [DOI] [PubMed] [Google Scholar]
  • 58.Macuamule CJ, Tjhin ET, Jana CE, Barnard L, Koekemoer L, de Villiers M, et al. A pantetheinase-resistant pantothenamide with potent, on-target, and selective antiplasmodial activity. Antimicrob Agents Chemother. 2015;59: 3666–3668. doi: 10.1128/AAC.04970-14 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Pett HE, Jansen PAM, Hermkens PHH, Botman PNM, Beuckens-Schortinghuis CA, Blaauw RH, et al. Novel pantothenate derivatives for anti-malarial chemotherapy. Malar J. 2015;14: 169. doi: 10.1186/s12936-015-0673-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Howieson VM, Tran E, Hoegl A, Fam HL, Fu J, Sivonen K, et al. Triazole substitution of a labile amide bond stabilizes pantothenamides and improves their antiplasmodial potency. Antimicrob Agents Chemother. 2016;60: 7146–7152. doi: 10.1128/AAC.01436-16 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Fletcher S, Lucantoni L, Sykes ML, Jones AJ, Holleran JP, Saliba KJ, et al. Biological characterization of chemically diverse compounds targeting the Plasmodium falciparum coenzyme A synthesis pathway. Parasit Vectors. 2016;9: 589. doi: 10.1186/s13071-016-1860-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.de Villiers M, Spry C, Macuamule CJ, Barnard L, Wells G, Saliba KJ, et al. Antiplasmodial mode of action of pantothenamides: pantothenate kinase serves as a metabolic activator not as a target. ACS Infect Dis. 2017;3: 527–541. doi: 10.1021/acsinfecdis.7b00024 [DOI] [PubMed] [Google Scholar]
  • 63.Weidner T, Lucantoni L, Nasereddin A, Preu L, Jones PG, Dzikowski R, et al. Antiplasmodial dihetarylthioethers target the coenzyme A synthesis pathway in Plasmodium falciparum erythrocytic stages. Malar J. 2017;16: 192. doi: 10.1186/s12936-017-1839-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Spry C, Sewell AL, Hering Y, Villa MVJ, Weber J, Hobson SJ, et al. Structure-activity analysis of CJ-15,801 analogues that interact with Plasmodium falciparum pantothenate kinase and inhibit parasite proliferation. Eur J Med Chem. 2018;143: 1139–1147. doi: 10.1016/j.ejmech.2017.08.050 [DOI] [PubMed] [Google Scholar]
  • 65.Guan J, Tjhin ET, Howieson VM, Kittikool T, Spry C, Saliba KJ, et al. Structure-activity relationships of antiplasmodial pantothenamide analogues reveal a new way by which triazoles mimic amide bonds. ChemMedChem. 2018;13: 2677–2683. doi: 10.1002/cmdc.201800327 [DOI] [PubMed] [Google Scholar]
  • 66.Spry C, Barnard L, Kok M, Powell AK, Mahesh D, Tjhin ET, et al. Toward a stable and potent coenzyme A-targeting antiplasmodial agent: structure-activity relationship studies of N-phenethyl-α-methyl-pantothenamide. ACS Infect Dis. 2020;6: 1844–1854. doi: 10.1021/acsinfecdis.0c00075 [DOI] [PubMed] [Google Scholar]
  • 67.Guan J, Spry C, Tjhin ET, Yang P, Kittikool T, Howieson VM, et al. Exploring heteroaromatic rings as a replacement for the labile amide of antiplasmodial pantothenamides. J Med Chem. 2021;64: 4478–4497. doi: 10.1021/acs.jmedchem.0c01755 [DOI] [PubMed] [Google Scholar]
  • 68.Warrenfeltz S, Basenko EY, Crouch K, Harb OS, Kissinger JC, Roos DS, et al. EuPathDB: the Eukaryotic Pathogen Genomics Database Resource. Methods Mol Biol. 2018;1757: 69–113. doi: 10.1007/978-1-4939-7737-6_5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Allen RJW, Kirk K. Plasmodium falciparum culture: the benefits of shaking. Mol Biochem Parasitol. 2010;169: 63–65. doi: 10.1016/j.molbiopara.2009.09.005 [DOI] [PubMed] [Google Scholar]
  • 70.Jacot D, Meissner M, Sheiner L, Soldati-Favre D, Striepen B. Genetic manipulation of Toxoplasma gondii. Toxoplasma gondii. Elsevier; 2014. pp. 577–611. doi: [DOI] [Google Scholar]
  • 71.Tjhin ET, Staines HM, van Schalkwyk DA, Krishna S, Saliba KJ. Studies with the Plasmodium falciparum hexokinase reveal that PfHT limits the rate of glucose entry into glycolysis. FEBS Lett. 2013;587: 3182–3187. doi: 10.1016/j.febslet.2013.07.052 [DOI] [PubMed] [Google Scholar]
  • 72.Shen B, Brown KM, Lee TD, Sibley LD. Efficient gene disruption in diverse strains of Toxoplasma gondii using CRISPR/CAS9. MBio. 2014;5: e01114–14. doi: 10.1128/mBio.01114-14 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.van Dooren GG, Tomova C, Agrawal S, Humbel BM, Striepen B. Toxoplasma gondii Tic20 is essential for apicoplast protein import. Proc Natl Acad Sci USA. 2008;105: 13574–13579. doi: 10.1073/pnas.0803862105 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Saliba KJ, Horner HA, Kirk K. Transport and metabolism of the essential vitamin pantothenic acid in human erythrocytes infected with the malaria parasite Plasmodium falciparum. J Biol Chem. 1998;273: 10190–10195. doi: 10.1074/jbc.273.17.10190 [DOI] [PubMed] [Google Scholar]
  • 75.Somogyi M. Determination of blood sugar. J Biol Chem. 1945;160: 69–73. doi: 10.1016/S0021-9258(18)43098-0 [DOI] [Google Scholar]
  • 76.Pei J, Grishin NV. PROMALS3D: multiple protein sequence alignment enhanced with evolutionary and three-dimensional structural information. Methods Mol Biol. 2014;1079: 263–271. doi: 10.1007/978-1-62703-646-7_17 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Pei J, Grishin NV. AL2CO: calculation of positional conservation in a protein sequence alignment. Bioinformatics. 2001;17: 700–712. doi: 10.1093/bioinformatics/17.8.700 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Xin-zhuan Su, Sean T Prigge

10 Mar 2021

Dear Professor Saliba,

Thank you very much for submitting your manuscript "A novel heteromeric pantothenate kinase complex in apicomplexan parasites" for consideration at PLOS Pathogens. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. In light of the reviews (below this email), we would like to invite the resubmission of a significantly-revised version that takes into account the reviewers' comments.

As you will see from the comments, all of the reviewers appreciate the work, the quality of the data and the contribution to the field. Reviewers 1, 2 and 3 suggest making relatively minor revisions, most of which are aimed at enhancing and clarifying different aspects of the results. Reviewer 4 made several suggestions and brought to your attention an article that was published today concerning PfPanK1 activity. In your response to the suggestions made by Reviewer 4, please pay specific attention to these points:

- Provide specific activity units in Figure 1c (as done in Fig 2).

- Determine the PanK activity of material (IP or lysate) from the Tg line TgPanK1-GFP/TgPanK2-mAIDHA after inducing knockdown of PanK2.

- Provide information about whether Tg14-3-3I can be detected with pan anti-14-3-3 in the TgPanK complex. Reviewer 1 also brought up this point.

We cannot make any decision about publication until we have seen the revised manuscript and your response to the reviewers' comments. Your revised manuscript is also likely to be sent to reviewers for further evaluation.

When you are ready to resubmit, please upload the following:

[1] A letter containing a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript. Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

[2] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Please prepare and submit your revised manuscript within 60 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email. Please note that revised manuscripts received after the 60-day due date may require evaluation and peer review similar to newly submitted manuscripts.

Thank you again for your submission. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.

Sincerely,

Sean T Prigge

Guest Editor

PLOS Pathogens

Xin-zhuan Su

Section Editor

PLOS Pathogens

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0001-5065-158X

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

***********************

As you will see from the comments, all of the reviewers appreciate the work, the quality of the data and the contribution to the field. Reviewers 1, 2 and 3 suggest making relatively minor revisions, most of which are aimed at enhancing and clarifying different aspects of the results. Reviewer 4 made several suggestions and brought to your attention an article that was published today concerning PfPanK1 activity. In your response to the suggestions made by Reviewer 4, please pay specific attention to these points:

- Provide specific activity units in Figure 1c (as done in Fig 2).

- Determine the PanK activity of material (IP or lysate) from the Tg line TgPanK1-GFP/TgPanK2-mAIDHA after inducing knockdown of PanK2.

- Provide information about whether Tg14-3-3I can be detected with pan anti-14-3-3 in the TgPanK complex. Reviewer 1 also brought up this point.

Reviewer's Responses to Questions

Part I - Summary

Please use this section to discuss strengths/weaknesses of study, novelty/significance, general execution and scholarship.

Reviewer #1: The manuscript from Tjhin and Howieson et al., describes the role of pantothenate kinase (PanK) in both P. falciparum and T. gondii, two pathogenic apicomplexan parasites. While PfPanK1 has been previously characterized, this manuscript shows that PfPanK1 forms a complex with PfPanK2 and Pf14-3-3I and that PfPanK2 is also a functional kinase within the complex. Furthermore, this manuscript characterizes the homologues TgPanK1 and TgPanK2 using conditional knockdowns that show that the two proteins are essential for growth, form a complex and contribute to PanK activity.

I have some minor considerations which I list out below:

1. In Figure 2C, right panel, in which we observe the immunoprecipitation of the Pf14-3-3 protein. Here I think it is important to include the Western blots that show that immunoprecipitation of the GFP tagged PfPanK1 and PfPank2 for the experiment as well as the GFP control. Please provide all relevant panels of the immunoprecipitation experiment so that the evaluation of the experiment is complete.

2. The authors speculate that the TgPanK1 and TgPanK2 complex also harbors another yet unidentified protein due to the increase in molecular weight. Did the authors try the pan 14-3-3 antibody on these T. gondii extracts? If a corresponding 14-3-3 homolog does not exist in T. gondii, it would be good to mention this in the text. If one does exist, it would be good to discuss whether the 14-3-3 antibody detected anything within the TgPanK1/2 complex, even if it was a negative result.

3. PanOH-A, PanOH-B and CJ-A harbour mutations in PfPanK1 and has been previously characterized. Nevertheless, it would have been helpful in the text to list the mutations in PfPanK1 that are present within these strains.

4. It is clear that TgPanK1 and TgPanK2 are essential for proliferation. Would the authors be able to provide any additional information about the nature of the death using cell biology techniques?

5. Can the authors comment on why they used SaPanK for the compensate for the PanK loss in the conditional knockdown vs using PfPanK1 or PfPanK2?

Reviewer #2: The authors present a comprehensive analysis of a previously unreported heterodimeric PanK present in two apicomplexan parasites. A combination of biochemical, proteomic, and cell biological techniques deomstrates the activity of this new form of PanK complex and confirms that both PanK proteins are essential for PanK activity and parasite survival. Overall, the work is thorough and complete. It is well presented, and the data supports the authors’ conclusions.

Given the quality of the work it is a bit disappointing that the explanation of the broader significance of the findings is not more explicit. It is implied that the study is of wider importance because the novel, heterodimeric nature of the apicomplexan PanKs might provide insight into the purpose of “non-functional” and non-canonical PanKs found in other organisms. This idea is not developed further in the discussion with, for instance, a comparison of the structure of “non functional” PanKs in apicomplexans and other organisms and a discussion of whether heteromeric PanKs might be biologically important beyond the apicomplexans. The importance of the heteromeric PanKs in anti-parasitic drug development is only briefly mentioned, with no discussion on the impact this new PanK structure might have in the context of known inhibitors and their development as new antimalarials. A revision of the Introduction and Discussion to provide a deeper insight into these topics would provide the non-expert reader a better understanding of why this previously unreported form of PanK is of general significance.

Reviewer #3: The manuscript “A novel heteromeric pantothenate kinase complex in apicomplexan parasites” by Tjhin et al describes functional characterization of a unique heteromeric pantothenate kinase in P. falciparum and T. gondii which is formed by association of PanK1 and PanK2 proteins. By using a combination of fluorescent microscopy, immunoprecipitation, mass spectroscopy and SDS-PAGE or native PAGE the authors demonstrate that both PfPanK1 and PfPanK2, along with another protein, Pf14-3-3I are part of pantothenate kinase complex. This was further supported by studies involving episomal expression of PfPanK2 in pantothenate kinase mutant strains of P. falciparum. Similar observations regarding heteromeric complex of PanK1 and PanK2 were made in another parasite T. gondii by using an auxin inducible degron fusion and immunoprecipitation techniques. A combination of knockdown and heterologous complementation by S. aureus type II Pank established the essentiality of PanK1 and PanK2 for the proliferation of T. gondii parasites.

P. falciparum and T. gondii are important pathogens causing human disease and there is an urgent need to discover drugs with novel mechanism of action for controlling these diseases. Pantothenate kinase has been suggested to be a drug target in a number of bacterial pathogens. The results of this study suggest that pantothenate kinase is a potential drug target in these two parasites as well. The formation of heteromeric enzyme complex by association of PanK1 and PanK2 also explains why individually expressed PanKs in heterologous systems had not shown any catalytic activity in a number of earlier studies.

This is a scientifically sound study which has clearly established the essential nature and catalytic activity of pantothenate kinase in P. falciparum and T. gondii. The conclusions drawn have been duly supported with proper experimentation. All the experiments have been designed logically with proper controls whenever required. The publication of this study will open up new avenues in pantothenate kinase research and will help in studies involving functional characterization of hitherto uncharacterized pantothenate kinases in prokaryotes and eukaryotes.

Reviewer #4: The authors aimed at demonstration of the significance of the presence of two PanK in apicomplexan parasites. They demonstrated that PfPanK1 and 2 likely form a dimer of 240 kDa by BN-PAGE, and that the complex possesses kinase activity toward pantothenate. The authors reciprocally identified PfPanK1 and PfPanK2 by immunoprecipitation from GFP-PfPanK1 or GFP-PanK2-expressing transformant lines with comparable efficiency. Notably 14-3-3I (and also M17 leucyl aminopeptidase) were also detected at the significant level, although its significance was not further examined. They created GFP-PfPanK expressing lines also in PanK-inhibitor-resistant lines (PanOH-A, PanOH-B, and CJ-A), which carry mutations in PfPanK1, but not PfPanK2 (?), gene. The ranking of the strains based on the PanK activity detected in the lysate of both control and GFP-PanK1 expressing tranformant line in wildtype and three resistant strains are the same as the ranking when immunoprecipitated samples were used as enzyme source, which only circumstantially supported PanK1 and GFP-PanK2 interaction. However, this observation can be also explained by possible up- or down-regulation of PfPanK1/2 gene expression, post-translational modifications, and interaction with other accessary proteins (such as those detected by MS analysis of the immunoprecipitated samples).

**********

Part II – Major Issues: Key Experiments Required for Acceptance

Please use this section to detail the key new experiments or modifications of existing experiments that should be absolutely required to validate study conclusions.

Generally, there should be no more than 3 such required experiments or major modifications for a "Major Revision" recommendation. If more than 3 experiments are necessary to validate the study conclusions, then you are encouraged to recommend "Reject".

Reviewer #1: None.

Reviewer #2: (No Response)

Reviewer #3: (No Response)

Reviewer #4: This is carefully designed and well executed experiments in order to understand the conundrum that some organisms possess two PanK-like proteins, using two representative apicomplexan parasites, Pf and Tg, as examples. Discovery of the complex formation and essentiality of the both PanK isotypes for PanK activity and proliferation (though the essentiality in Pf was previously demosntrated) is a major contribution of the study to the fields. However, how the regulation of PanK activity by PanK2, e.g., via modulation of stability or protein complex conformation, remains totally undetermined. Furthermore, its relevance to pathogenesis of the two parasites are also not properly discussed. These two issues are more or less the critical points that need to be clarified. In addition, two additional critical missing points here are: they did not demonstrate stoichiometry of the two isotypes in the complex (e.g., the ratio of the components). Activity was simply shown as arbitrary (?) radio isotope counts, but not in specific activity (e.g., Fig. 1C), thus it was not evaluated that the complex is as active as detected in the whole cell lysate. In addition, PanK activity was not demonstrated using individual isoform of PfPanK1 and 2. The following recent paper demonstrated PanK1 activity using a single E. coli recombinant protein (not as a heterocomplex with PanK2) (Nurkanto et al., Front Cell Inf Microbiol, 2021; doi: 10.3389/fcimb.2021.639065). Thus, the biological significance of the heterodimer of PfPanK can be demonstrated using the two PfPanK recombinants.

Specific points:

Fig. 1b: Both PfPanK1-GFP and PfPanK2-GFP appear to be present as multiple truncated and untruncated forms (e.g., PfPanK1-GFP, ca 30, 38, 49, and 60kDa and 70-80 kDa untruncated form)(PfPanK2-GFP, ca 40, 60 kDa and -100kDa). It is important to know if such truncated forms also retains binding ability with PanK1 and 14-3-3I, and other possible accessory factors, and moreover if the truncated forms are also retain activity. The authors must address those points using recombinant proteins.

It is also important to note there is an additional complex (?) at -140kDa detected in the sample immunoprecipitated from PfPanK1-GFP only. After all, it is not clear at all which of the two isotypes is responsible for catalytic and regulatory? activities. Based on Tg KD experiments, it was shown that both isotypes are necessary for Tg proliferation. How about PanK activity? Specific KD of TgPanK1 or 2 reduces PanK activity in a time-dependent fashion?

Significance of interaction with 14-3-3I was intriguing; however, no further evidence for a potential involvement of 14-3-3I in influence on PanK activity, its synthesis and turnover, have not been provided. Neither was for other PanK1/2 associated proteins. Proteome data were not fully utilized and downstream research is rather superficial and sufficient for publication in PLoS Pathogens. They proposed in discussion section that Pf14-3-3I plays a regulatory role in the PfPanK complex. At least, conditional knockdown by GlnS-ribozyme-based conditional KO or destabilizing domain-based KD of Pf14-3-3I can be tried to see if PfPanK1/2 gene expression, protein localization, and function are affected. Furthermore, since 14-3-3I was not identified by immunoprecipitated from Tg, generalization of the possible interaction of PanK with 14-3-3I in apicomplexa should not be made. It was argued that the proteome of TgPanK was unsuccessful, but the whole content of the manuscript was intended to generalize the heteromeric formation of PanK for its activity, so it is indeed a pity if the proteomic analysis of TgPanK complex is not included in this study. This referee feels it is needed to include this for the completion of the present study if they generalize the observation for apicomplexa.

**********

Part III – Minor Issues: Editorial and Data Presentation Modifications

Please use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity.

Reviewer #1: Please see Part 1 summary

Reviewer #2: I addition to a revision of the Introduction and Discussion mentioned above, I would suggest some editing of the section describing the PfPanK immunoprecipitations. The experiments are excellent but the naming of the recombinant proteins and the multiple uses of GFP tags to pull down different complexes can make the details hard to follow. A minor reworking of this section and figures to emphasize which PanK is being expressed in each cell line (the type of tag is not as important), which protein is being immunoprecipitated, and which is being co-immunoprecipitated, would make the experiments easier to follow and the results easier to interpret. The inclusion of a diagram(s) in Figure 1/2 outlining the experimental approach would be helpful. While the description of the T. gondii immunoprecipitations was clearer, a diagram of these experiments would also be helpful.

Minor edits:

Line 41-43 should read “Interestingly, many eukaryotes (such as Arabidopsis thaliana 11,12, Mus musculus 13-16 and Homo sapiens 17-21) express multiple PanKs.”

Line 61: the comma after PfPank2 isn’t needed.

Line 341: “likely” can be deleted.

Figure 2a: the inclusion of M17 leucyl-aminopeptidase as the fourth most abundant protein in the text and in column two is a bit misleading. There are other proteins with more peptides recovered in the PanK2 immunoprecipitation and this should be made clearer.

Reviewer #3: (No Response)

Reviewer #4: The title seems to be a bit too general, and the observations should not be generalized to the apicomplexa as evidence was provided only on P. falciparum and T. gondii. It would be nice if the authors touch upon other apicomplexan parasites such as Eimeria spp., Theileria spp., and Cryptosporidium?

Figure 1C: Is it possible to prolong incubation to reach phosphorylation close to 100%?

Figure 2C: In control, the lysate of the line expressing GFP only did not show any PanK activity (pantothenate phosphorylating) up to 90 min. However, it is thought that in control, the endogenous PanK activity must be detected in the lysate (maybe low activity). Please explain.

“PfPanK1 and PfPanK2 are part of an active PanK enzyme complex in P. falciparum parasites”. However, one can also argue that PfPanK and 2 make a complex, but only PfPanK1 possesses an enzymological and physiological role. The evidence to claim the statement need to be provided (for instance, make a Pf mutant by removing only one of PfPanK1 and PfPanK2 genes)(if genes not being essential, though), to detect any decrease of PanK activity.

5. Fig 3B clearly showed that TgPanK1 and TgPanK2 play independent but cooperative roles for pantothenate phosphorylation. Provide any explanation on any expected specific roles of TgPanK1 and 2 in PanK activity in this parasite?

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Wai-Hong Tham

Reviewer #2: No

Reviewer #3: Yes: Umender Sharma

Reviewer #4: No

Figure Files:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

Data Requirements:

Please note that, as a condition of publication, PLOS' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here on PLOS Biology: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5.

Reproducibility:

To enhance the reproducibility of your results, PLOS recommends that you deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see http://journals.plos.org/plospathogens/s/submission-guidelines#loc-materials-and-methods

Decision Letter 1

Xin-zhuan Su, Sean T Prigge

13 Jul 2021

Dear Professor Saliba,

We are pleased to inform you that your manuscript 'A novel heteromeric pantothenate kinase complex in apicomplexan parasites' has been provisionally accepted for publication in PLOS Pathogens.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Pathogens.

Best regards,

Sean T Prigge

Guest Editor

PLOS Pathogens

Xin-zhuan Su

Section Editor

PLOS Pathogens

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0001-5065-158X

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

***********************************************************

Reviewer Comments (if any, and for reference):

Acceptance letter

Xin-zhuan Su, Sean T Prigge

23 Jul 2021

Dear Professor Saliba,

We are delighted to inform you that your manuscript, "A novel heteromeric pantothenate kinase complex in apicomplexan parasites," has been formally accepted for publication in PLOS Pathogens.

We have now passed your article onto the PLOS Production Department who will complete the rest of the pre-publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Pearls, Reviews, Opinions, etc...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript, if you opted to have an early version of your article, will be published online. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Pathogens.

Best regards,

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0001-5065-158X

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. List of proteins identified in the MS analysis of the GFP-Trap immunoprecipitated complexes from PfPanK1-GFP and PfPanK2-GFP lines.

    Proteins detected in each immunoprecipitation experiment are listed in descending order according of the total number of peptides detected across the two replicates (total peptides in 1st and 2nd rep columns). Only proteins that are present in the immunoprecipitation fractions of both parasite lines and absent in the negative controls (bound fractions of untagged GFP and 3D7 parasite lysates) are shown. Proteins shown in Fig 2A are indicated in red.

    (TIF)

    S2 Table. List of oligonucleotides used in this study.

    (TIF)

    S3 Table. List of gBLOCK sequences used in this study.

    (TIF)

    S1 Fig. Overview of experimental workflow.

    Flow chart highlighting the cell lines generated for the study and the main experimental steps that were performed. The coloured arrows represent final experimental results, and the associated figures within which the data are presented, are indicated under each experiment.

    (TIF)

    S2 Fig. GFP-Trap immunoprecipitation of proteins from PfPanK1-GFP, PfPanK2-GFP and untagged GFP lines.

    Denaturing western blot analysis of the GFP-tagged proteins present in the total lysate, unbound and GFP-Trap-bound fractions of PfPanK1-GFP, PfPanK2-GFP and untagged GFP lines. Western blots were performed with anti-GFP antibody and the blot shown is representative of two independent experiments each performed with a different batch of parasites.

    (TIF)

    S3 Fig. MS coverage of PfPanK1.

    PfPanK1 peptides detected in the two independent MS analyses of the GFP-Trap immunoprecipitation from the PfPanK1-GFP and PfPanK2-GFP lines. Residues in green were detected in either analysis with >95% confidence, while residues in orange were detected in either analysis with >90% (but <95%) confidence. Percentage coverage was calculated using only the residues labelled green.

    (TIF)

    S4 Fig. MS coverage of PfPanK2.

    PfPanK2 peptides detected in the two independent MS analyses of the GFP-Trap immunoprecipitation from the PfPanK1-GFP and PfPanK2-GFP lines. Residues in green were detected in either analysis with >95% confidence, while residues in orange were detected in either analysis with >90% (but <95%) confidence. Percentage coverage was calculated using only the residues labelled green.

    (TIF)

    S5 Fig. MS coverage of Pf14-3-3I.

    Pf14-3-3I peptides detected in the two independent MS analyses of the GFP-Trap immunoprecipitation from the PfPanK1-GFP and PfPanK2-GFP lines. Residues in green were detected in either analysis with >95% confidence, while residues in orange were detected in either analysis with >90% (but <95%) confidence. Percentage coverage was calculated using only the residues labelled green.

    (TIF)

    S6 Fig. Determining the amount of GFP-Trap bound PfPanK2-GFP for pantothenate phosphorylation assays.

    (A) The proportion of GFP-positive saponin-isolated 3D7, Parent+PfPanK2-GFP, PanOH-A+PfPanK2-GFP, PanOH-B+PfPanK2-GFP and CJ-A+PfPanK2-GFP trophozoites was determined by FACS analysis. The forward scatter (FSC) intensity on each x-axis corresponds to cell size and the y-axis corresponds to the intensity of GFP fluorescence. The proportion of GFP-positive cells in each transgenic line (percentage value in each plot) was determined by using 3D7 trophozoites to set a gating threshold below which parasites were defined to be auto-fluorescent. Data shown are representative of three independent experiments, each performed prior to the [14C]pantothenate phosphorylation assays presented in Fig 2B(ii). The flow cytometry data were used to standardise the amount of PfPanK2-GFP immunoprecipitated from each cell line used in each [14C]pantothenate phosphorylation assay. (B) Denaturing western blot analysis of PfPanK2-GFP in the GFP-Trap immunoprecipitated complexes that were used in the [14C]pantothenate phosphorylation assays performed to generate the data in Fig 2B(ii). Western blots were performed with an anti-GFP antibody and each blot shows the relative amounts of PfPanK2-GFP immunopurified from the four different cell lines used in each of the three [14C]pantothenate phosphorylation experiment. The same volume of samples (10 μL per lane) was used for all three experiments.

    (TIF)

    S7 Fig. Multiple sequence alignment of representative Type II PanKs.

    The conserved PHOSPHATE 1, PHOSPHATE 2, and ADENOSINE 1 motifs of the acetate and sugar kinases/Hsc70/actin (ASKHA) superfamily of kinases are labelled at the top of the alignment. The Glu (E) residue involved in catalysis and the Arg (R) residue involved in positioning the substrate, are shown on a black background. Residues that have been found to interact with pantothenate and acetyl-CoA in human PanK3 [34,35] are marked with a blue asterisk. Residues that were found to interact to stabilise the human PanK3 active site are marked with a red asterisk. The catalytic Glu (E) residue is marked with a red and blue asterisk as it is involved in both the interaction with pantothenate and the stabilisation of the active site through interaction with a Tyr (Y) residue of the opposite protomer. The numbers at the start and end of each sequence indicate the position of the first and last residue in the alignment, respectively. The lengths of insertions are specified within the square brackets and the total length of protein sequences are shown in round brackets. Residues within the ASKHA superfamily motifs and conserved residues are highlighted based on the consensus AA guide for the column as follows: identical = bold, hydrophobic (W,F,Y,M,L,I,V,A,C,T,H) = yellow, charged/polar/small (D,E,K,R,H/D,E,H,K,N,Q,R,S,T/A,G,C,S,V,N,D,T,P) = grey and Gly (G) = red. The two insertion regions (Ins 1 and Ins 2) common to eukaryotic type II PanKs, but absent in prokaryotic PanKs are indicated by the black horizontal bars, while the PfPank1/TgPanK1 and PfPanK2/TgPanK2 specific inserts are highlighted on a red and blue background, respectively. Conservation refers to the conservation index [77]. Values at and above the conservation index cut-off (5) are displayed above the amino acid. Consensus AA: refers to the consensus level alignment parameters for the consensus amino acid sequence. This is displayed if the weighted frequency of a certain class of residues in a position is above 0.8. Consensus symbols: conserved amino acids are in bold and uppercase letters; aliphatic (I, V, L): l; aromatic (Y, H, W, F): @; hydrophobic (W, F, Y, M, L, I, V, A, C, T, H): h; alcohol (S, T): o; polar residues (D, E, H, K, N, Q, R, S, T): p; tiny (A, G, C, S): t; small (A, G, C, S, V, N, D, T, P): s; bulky residues (E, F, I, K, L, M, Q, R, W, Y): b; positively charged (K, R, H): +; negatively charged (D, E): -; charged (D, E, K, R, H): c. Marked below the alignment, 85% consensus includes those residues that occur in either the superfamily motifs and/or conserved residues where the same residue occurs more than 85% (10 out of 13 sequences). Consensus secondary structure (ss) elements: h = alpha helix, e = beta strand. Species names are abbreviated as follows: Sa = Staphylococcus aureus, Sc = Saccharomyces cerevisiae, An = Aspergillus nidulans, Hs = Homo sapiens, At = Arabidopsis thaliana, Pf = Plasmodium falciparum and Tg = Toxoplasma gondii. The alignment was created using PROMALS3D [76].

    (TIF)

    S8 Fig. Schematic of the native and modified pank genomic loci in T. gondii and verification of the incorporation of the coding sequence for various epitope tags into the Tgpank1 and Tgpank2 loci.

    (A) Schematic of theTgpank1 and Tgpank2 genomic loci, indicating the incorporation sites of the epitope tag coding sequence. The expected sizes of the PCR products when screened with each set of screening primers are shown above the corresponding epitope tag coding sequence. The screening primers are Tgpank1 screen fwd and rvs for Tgpank1 (referred to as Tgpank1 primers in panels B-D), and Tgpank2 screen fwd and rvs for Tgpank2 (referred to as Tgpank2 primers in panels B-D). Primers are detailed in S2 Table. (B) PCR analysis of the parental strain (TgParent), and singly-tagged TgPanK1-mAIDHA and TgPanK2-mAIDHA lines. Both TgPanK1-mAIDHA and TgPanK2-mAIDHA have successfully incorporated mAIDHA tags. (C) PCR analysis of the doubly-tagged TgPanK1-GFP/TgPanK2-mAIDHA line. CRISPR/Cas9 was utilised to incorporate a sequence encoding a TEV-GFP tag into the genomic locus of the Tgpank1 gene within the TgPanK2-mAIDHA line. (D) PCR analysis of the TgPanK1-HA/TgPanK2-GFP doubly-tagged line. CRISPR/Cas9 was utilised to incorporate a sequence encoding a TEV-HA tag into the genomic locus of the Tgpank1 gene and a sequence encoding a TEV-GFP tag into the genomic locus of the Tgpank2 gene.

    (TIF)

    S9 Fig. Anti-GFP and anti-HA immunoprecipitation of TgPanK1-HA/TgPanK2-GFP expressing parasites.

    Anti-HA and anti-GFP denaturing western blot analysis of fractions from GFP-Trap and anti-HA immunoprecipitations performed using lysates prepared from the parasite lines expressing TgPanK1-HA/TgPanK2-GFP. The expected molecular masses of TgPanK1-HA and TgPanK2-GFP are 136 kDa and 206 kDa, respectively. The blot shown is representative of three independent experiments, each performed with a different batch of parasites. Denaturing western blots were also probed with anti-TgTOM40, which served as a control for a protein that is not part of the PanK complex.

    (TIF)

    S10 Fig. Absence of 14-3-3 from the TgPanK heteromeric complex.

    Anti-HA, anti-GFP and anti-14-3-3 denaturing western blot analysis of fractions from GFP-Trap immunoprecipitation of lysates prepared from the parasite line expressing TgPanK1-GFP/TgPanK2-mAIDHA. The expected molecular masses of TgPanK1-GFP, TgPanK2-mAIDHA and 14-3-3 are approximately 160 kDa, 189 kDa and 37 kDa, respectively. The blots shown are representative of two independent experiments, each performed with a different batch of parasites.

    (TIF)

    S11 Fig. Expression of SaPanK-Ty1 in parasites expressing TgPanK1-mAIDHA and TgPanK2-mAIDHA.

    (A) Anti-HA and anti-Ty1 denaturing western blot analysis of SaPanK-Ty1-complemented and non-complemented (i) TgPanK1-mAIDHA and (ii) TgPanK2-mAIDHA lines, in the absence or presence (for 1 h) of 100 μM IAA. The expected molecular masses of TgPanK1-mAIDHA, TgPanK2-mAIDHA and SaPanK-Ty1 are ~143 kDa, ~189 kDa and ~29 kDa, respectively. Denaturing western blots were also probed with anti-TgTOM40, which served as a loading control. Each blot shown is representative of three independent experiments, each performed with a different batch of parasites. (B) Fluorescence micrographs of a HFF cell infected with four tachyzoite-stage TgPanK1-mAIDHA+SaPanK-Ty1 parasites within a vacuole, indicating the presence of SaPanK-Ty1. From left to right: Differential interference contrast (DIC), tdTomato RFP (a marker of the nucleus and cytosol; red), anti SaPanK-Ty1 (green), and merged images. Scale bar represents 2 μm.

    (TIF)

    S12 Fig. Pantothenate binding site and interactions in H. sapiens PanK3.

    (A) H. sapiens AMP-PNP-pantothenate-bound PanK3 crystal structure (PDB ID: 5KPR, Subramanian et al. [35]). The homodimeric protein is made up of two identical protomers (lilac and yellow) forming two identical active sites, each binding pantothenate (carbon atoms shown in green). The red square encompasses one of the active sites. (B) Magnification of the region outlined by the red square in (A). Residues from both protomers contribute to the stabilisation of the binding pocket (E138 forms a hydrogen bond with Y254’ and D137 with Y258’) and interact with pantothenate (E138, S195, R207, A269’ and V268’). Hydrogen bonds with and between the sidechains of these residues are shown in red. An apostrophe denotes residues from the lilac protomer. (C) List of residues annotated in the HsPanK3 model that participate in the stabilisation of the binding pocket (highlighted cyan), and a comparison to the equivalent residues in P. falciparum and T. gondii PanKs. The PanKs from P. falciparum and T. gondii do not individually contain the complete set of residues required for the stabilisation of the binding pocket, but the combination of residues (highlighted cyan) from PanK1 and PanK2 suggests that each PanK1/PanK2 heterodimer will have only one stabilised binding site.

    (TIF)

    S13 Fig. Multiple sequence alignment of active site stabilisation residues in apicomplexan PanKs.

    The apicomplexan PanK residues corresponding to the HsPanK3 residues that are involved in the stabilisation of the binding pocket (D137, E138, Y254 and Y258) are highlighted in cyan if they are conserved and in grey if they are not conserved. The numbers before each alignment indicate the position of the first residue in the alignment. Each apicomplexan PanK is grouped into PanK1 or PanK2 based on their similarity to either PfPanK1/TgPanK1 or PfPanK2/TgPanK2, respectively. The alignment was created using PROMALS3D [76].

    (TIF)

    S1 Text. Supplementary Methods.

    (DOCX)

    Attachment

    Submitted filename: Response to Reviewers.pdf

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting Information files.


    Articles from PLoS Pathogens are provided here courtesy of PLOS

    RESOURCES